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ABSTRACT 
 
Fusobacterium nucleatum is a Gram-negative anaerobic bacterium prevalent in the human oral 
cavity. This oral commensal bacterium has been shown as the main contributor for many dental 
diseases, including periodontitis and gingivitis. Recently, evidence has verifying the linkage 
between F. nucleatum and carcinogenesis of colorectal cancer (CRC). Outer membrane vesicles 
(OMVs) are naturally occurring metabolic byproducts secreted by Gram-negative bacteria, and 
contain highly antigenic LPS and outer membrane protein residues. Due to its antigen containing 
and non-self-replicated properties, OMVs are emerging as a powerful platform for vaccine design 
and delivery. We speculated the OMVs from F. nucleatum might contain antigens able to elicit 
effective immune response. In this study, we identified 98 proteins from purified OMVs of F. 
nucleatum through proteomic studies. In silica analysis indicates the non-replicative OMVs of F. 
nucleatum contain a variety of antigenic virulence factors and may play a critical role in vaccine 
design. 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
 
The gastrointestinal (GI) track has the largest internal surface area in the human body and harbors 
several trillion microorganisms 1. As the main segments of GI track, intestines are heavily 
colonized by complex and dynamic microbial communities. In the past, the role of microbiota was 
neglected, while in recent years this view has dramatically changed as researchers have uncovered 
the fact that microorganisms play a crucial role in host homeostasis and disease, ranging from 
obesity and infectious disease to neurodegenerative diseases 2-3. Five major phyla Actinobacteria, 
Bacteroidetes, Firmicutes, Proteobacteria and Verrucomicrobia make up the bulk of intestinal 
microbiota, which is highly diverse and abundant 4. Studies have long established causation or 
association of main gut bacteria including Clostridium difficile (a key member of Firmicutes), 
Escherichia coli (a key member of Proteobacteria), Bacteroides fragilis (a key member of 
Bacteroidetes) and Fusobacterium nucleatum with dysbiosis and multiple human diseases such as 
inflammatory bowel disease (IBD) and colorectal carcinoma (CRC) 5-7. Recently, the composition 
of intestinal flora has proven strongly correlated with diet and hygiene; investigations linking 
diseases progression with intestinal microbial communities are still ongoing.  
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1. 1 Fusobacterium nucleatum 
1.1.1 Biology and Taxonomy of Fusobacterium nucleatum 
Fusobacterium nucleatum is a Gram-negative non-sporefroming and obligate anaerobic (up to 6% 
oxygen) bacterium with fusiform rod shape; it is a key component of plaque and a common resident 
of human oral cavity 8-9.  It is a heterogeneous species and one of the most abundant organisms 
identified among endodontic infections 8, 10. The name of Fusobacterium came from fusus and 
bacterion, which means spindle and rod 8.  
 
In 1693, Antony van Leeuwenhock first detected the fusiform organisms from dental plaque, and 
later in 1894 and 1896, the bacteria were found in gingivitis samples and angina by Plaut and 
Vincent, respectively 11. The fusiform bacteria were first isolated from the culture in 1898 by 
Veillon and Zuber and named Bacillus fusiformis 11.  In 1907 Leiner first recognized different 
culture types, and in 1913 Krumwied and Pratt first classified the fifteen strains into two groups 
based on their fermentability of sucrose 12. In 1922, Knorr proposed the genus Fusobacterium and 
named three subspecies: nuceatum, polymorphum, and plauti-vincentii 8, 11-12. In 1990 and 1992, 
Dzink et.al and Gharbia et.al grouped Fusobacterium into five subspecies: nucleatum, 
polymorphum, fusiforme, animalis, and vicentii 8, 11, 13. Up to 2002, there were totally six 
subspecies been recognized including F. canifelium, which is isolated from cat and dog bite 
wounds in human 14. Accumulating evidence has indicated among all subspecies F. nucleatum are 
frequently associated with diseases, which including periodontitis, adverse pregnancy outcomes, 
Lemierre’s syndrome, inflammatory bowel disease, and colorectal cancer 15.  
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Figure 1  Microscope image of F. nucleatum 
Gram stain of F. nucleatum appears red. F. nucleatum is an anaerobic bacterium with slender and 
spindle shape under the microscope.  
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1.1.2 Pathogenesis 
F. nucleatum was first identified among plaque and found associated with dental disease. With the 
advancement and magnificent of experimental technology F. nucleatum was found prevalent 
among humans and has been implicated not only various oral diseases but GI disorders and other 
chronic infections such as Lemierre's syndrome and Alzheimer's disease as well 15-17. As an oral 
commensal bacterium, F. nucleatum pervades the host mainly by colonization and dissemination 
to invade the epithelial cells 15.  Several virulence factors encoded by F. nucleatum such as FadA, 
Fap2, and RadD were shown able to adhere and interact with host cells 18-20.  
 
FadA is the best-characterized adhesion molecule and uniquely encoded by F. nucleatum.  It has 
an alpha-helical hairpin structure 20. There are two forms of FadA: pre-FadA (nonsecreted from) 
containing 129 amino acids and mature FadA (secreted form) containing 111 amino acids 20.  A 
mixture of pre-FadA and mature FadA results in attachment to intestinal epithelium; however, 
preparations of mature FadA show no binding 20. In addition to adhesion, induction of host immune 
response is another key virulence mechanism of F. nucleatum. To stimulate colorectal tumor 
progression, FadA binds to the E-cadherin receptor and actives β-catenin, resulting in upregulation 
of transcriptional factors, Wnt genes, inflammatory gene and oncogenes 21.  
 
Another CRC associated virulence factor is lectin Fap2, a galactose adhesion protein that 
recognizes Gal-GalNAc, facilitates localization and colonization of F. nucleatum on CRC cell 22.  
Additionally, Fap2 suppresses T cells and natural killer (NK) cells activities by directly interacts 
with inhibitory receptor TIGIT to evade the immune system attack 23.  
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1.1.3 F. nucleatum in Periodontal Disease  
Porphyromonas gingivalis, Streptococcus sangius, Streptococcus gordonii, Tannerella forsythia, 
Treponema denticola, Actinobacillus actinomycetemcomitans, and F. nucleatum were primary 
etiologic agents of periodontitis 8, 24-25. F. nucleatum is abundant in human oral cavity and is 
present in much higher levels in patients with periodontitis and gingivitis 25-28.  Samples collected 
from patients with gingivitis, chorionic periodontitis, and healthy groups were analyzed by real-
time PCR and the experimental results displayed that the occurrence of F. nucleatum was 
positively correlated with the progression of the disease 25-26. The elevation of IgG and IgA 
response levels were also detected in chronic periodontal patients 29. It has been implied the 
combination of F. nucleatum and P. gingivalis or other bacterium was more pathogenic than F. 
nucleatum only infection 8, 30.  F. nucleatum recognized lactose, galactose and other sugars of P. 
gingivalis capsid and conjugated with these though carbohydrate-hydrate interaction 31-32. The 
corncob receptor of F. nucleatum interacts with P. gingivalis to form coaggregation units, playing 
an essential role in attachment and plaque formation 24, 33-35. In addition, F. nucleatum had the 
ability to reduce oxygen in the microenvironment thus facilitating P. gingivalis growth to promote 
periodontitis 36.  
 
1.1.4 F. nucleatum in Colorectal Carcinoma 
The primary role of F. nucleatum in the aetiology of CRC was revealed recently and has emerged 
as a focus of study. These studies have shown that presence of F. nucleatum, previously considered 
only as an intestinal commensal, has been linked with CRC progression and metastasis as an 
essential risk factor 37-38.  F. nucleatum bacterial loads from colorectal tumor tissue samples were 
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significantly higher compared with adjacent normal tissues tested using qPCR 37, 39. This indicated 
that F. nucleatum could be used as a putative biomarker for CRC diagnoses. Recent studies have 
also indicated that F. nucleatum not only participated colorectal carcinogenesis but was 
interrelated with CRC outcomes as well 38. Flanagan et al. discovered low F. nucleatum loads in 
cancer patients’ tissue corresponded to longer survival times; conversely, moderate and high 
bacterial loads corresponded to shorter survival times 38. Another study also confirmed similar 
results and implied F. nucleatum might serve as a CRC prognosis marker 40.  
 
As previous discussed, FadA and Fap2 are two virulence factors participating in tumorigenesis. 
FadA adhesion is highly conserved in F. nucleatum, and binds to E-cadherin on intestinal epithelial 
cells, inducing beta-cadherin signaling leading to Wnt, oncogene, and transcription factor 
expression, further promoting uncontrolled cell proliferation and inflammatory responses 21. In 
vivo studies revealed that nude mice inoculated with CRC cells displayed a tumor mass increase 
of 20 % when followed with FadA treatment for 21 days post inoculation 21. Additionally, FadA 
expression levels in CRC patient colon tissues is significantly higher than in healthy control 21. 
Fap2 has been shown to actively bind Gal-Gal-NAc, a polysaccharide over expressed in human 
colorectal adenocarcinoma. This binding activity contributes to the abundance of Fusobacteria in 
CRC 22. Fap2 directly actives TIGIT receptors, inhibitors of NK cell and T cell activity 21, 23. 
Briefly, Fap2 is recognized by TIGIT receptor; Fap2/TIGIT binding inhibits NK cell cytotoxicity 
and T cell activity, avoiding immune attack.  Fap2mut F. nucleatum is not able to bind to TIGIT, as 
indicated using hemagglutinin binding assays 23. 
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1.1.5 F. nucleatum in Other Human Diseases  
In addition to periodontal disease and CRC, F. nucleatum also widely associate with other systemic 
diseases. Adverse pregnancy outcomes (APO), including preterm birth, preterm premature rupture 
of membranes, stillbirth, neonatal sepsis etc. was found to be correlated  to periodontitis, and F. 
nucleatum was one of the predominant oral species found among placental and fetal tissues that 
were found to be closely associated with APO 41. Animal studies indicated F. nucleatum migrated 
through hematogenous transmission from the oral cavity to the placenta, inducing APO 42. Studies 
have revealed that the fetal loss rate was significantly reduced in F. nucleatum challenged Toll-
like receptor 4 (TLR4) knockout mice compared with wild type mice, and accompanying 
necroinflammatory responses was also decreased, which suggests that F. nucleatum induced fetal 
death via a TLR4 modulated immune response 43-44. F. nucleatum is also a major cause of 
Lemierre’s Syndrome, a complication of pharyngitis in adolescents 45-46. Additional diseases 
including inflammatory bowel disease, appendicitis, atherosclerosis, cerebral aneurysm, 
rheumatoid arthritis and Alzheimer's disease were also observed with F. nucleatum 15.  
 
1.2 Colorectal Carcinoma 
1.2.1 Epidemiology  
The abnormal cell growth in the colon or rectum is regarded as CRC. It is the fourth leading cancer-
caused death and third most common malignancy worldwide 47. According to the statistic from 
World Health Organization in 2012, the incidence rate was highest in Korea following by Slovakia 
and some developed countries in Europe, whereas lowest rates occurred in Asian and African 
countries 48. Epidemiological analysis indicated CRC rates was positively associated with the 
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human development index (HDI) 47. The mortality rate was highest in Hungary, while lowest rates 
occurred in some countries in Africa 48. While the trend of incidence and mortality varied, 
morbidity and mortality rates decreased in some high-income countries, probably due to better 
health care systems in place enabling early diagnosis and treatment 47, 49.  It was speculated that 
the CRC incidence and mortality rates are linked with HDI where 47, 49.  
 
CRC typically presents no symptoms in the early stages, while as the tumor enlarges, obstruction 
occurs in the intestine.  Risk factors associated with CRC are complex, and some factors like age, 
sex, family history, and inflammatory bowel disease are positively correlated with CRC risk. 
However, some medical factors including large bowel endoscopy, hormone replacement therapy, 
and aspirin are negatively related with CRC risk 49. Rapidly evolving experimental techniques and 
accumulating lines of evidence show that F. nucleatum, E.coli, B. fragilis and other potential 
infectious bacteria may participate in CRC development and progression 50. 
 
1.2.2 CRC Carcinogenesis and Metastasis  
CRC typically starts from adenoma, a noncancerous growth, and often remains dormant in colon 
or rectum for decades 51. Only fewer than 10% of the adenoma progress into cancer, though all 
adenomatous polyps have carcinogenic potential 52. Once precursor adenomas leave the dormant 
stage they grow larger and develop into adenocarcinomas, infiltrating into the intestinal epithelium 
49. These masses are often metastatic, shedding cells that circulate to lymph nodes and other organs 
via blood vessels 49. The molecular factors of CRC are heterogeneous though mutated oncogenes 
and tumor suppressor genes are assumed to play a role in adenocarcinogenesis 53. In this process, 
KRAS oncogene is activated and tumor suppressor gene TP53 expression is suppressed 49, 53. This 
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is accompanied by chromosomal instability, and the promotion of carcinogenesis 49, 53. DNA repair 
mismatch is another mechanism leading to microsatellite instability, which accelerates CRC 
formation 49. Additionally, inherited traits may play a role in the molecular pathogenesis in CRC 
49. CRC patients often develop liver, lung and brain metastases, though the mechanisms governing 
metastasis are not well characterized 54-56.   
 
1.2.3 CRC Prevention and Therapy  
Three levels of preventative measures are used to reduce probability of CRC development. Firstly, 
a healthy lifestyle and diet are seen as an essential for primary prevention. Avoiding some potential 
risk factors like smoking, obesity, and high consumption of red meat may greatly reduce CRC 
incidence49. Studies also suggested chemoprevention supplements such as aspirin and vitamin D 
can reduce CRC 49. A secondary preventive measure is early diagnosis and screening, which 
includes visual examination and stool tests. Colonoscopy is one typical and recommend method 
for visual examination that can reduce incidence and mortality rates  significantly 58. The fecal 
occult blood test is a highly specific but insensitive stool screen, which is a non-invasive and 
valuable measure for reducing CRC 59-60.  A third preventive category is risk reducing lifestyle 
choices. Exercise and smoking cessation are proven behaviors, which enhance general health and 
may significantly reduce CRC incidence49. Surgery is a standard and main treatment for non-
metastasized CRC.  Adjuvant therapy is recommended for stage III CRC and some other high-risk 
cases 49, 61.   
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1.3 Bacterial Outer Membrane Vesicles 
1.3.1 Outer Membrane Vesicles Biogenesis 
Outer membrane vesicles (OMVs) are a powerful new drug and vaccine delivery system. OMVs 
are spontaneously produced by Gram-negative bacterium as a result of normal bacterial 
metabolism 62. Gram-negative bacteria possess two membranes, the outer and inner (or 
cytoplasmic) membranes; in between lies a periplasmic fraction mainly contain peptidoglycan 63. 
OMVs disassociate from the bacterial outer membrane and are secreted outward. OMVs are loaded 
with outer membrane proteins and consist of phospholipid and lipopolysaccharide (LPS), and some 
periplasmic proteins. Although the OMVs were originally identified in lysed bacterial preparations, 
later studies demonstrated these vesicles to be present without cell disruption 62. It has been proven 
the biogenesis of OMVs cargo is selected and premeditated, in response to environmental stresses 
including nutrient shortfall, oxidation, antibiotics, and others 64.  Additionally, OMVs isolated 
from a given batch or culture may contain a wide variety of different components 62. OMV 
biogenesis starts when outer membrane bulges certain localized section form, and detach from the 
underlying peptidoglycan layer 65. After bulge formation, vesicles are released spontaneously from 
the outer membrane layer 65. The vesiculation process is very random; components of the 
peptidoglycan layer, portions of the inner membrane, and even contents of the cytosol located near 
a budding vesicle may become incorporated as vesicle contents or cargo.  
 
1.3.2 Composition and Functions  
The vesiculation process is a nearly universal process seen in Gram-negative bacteria; even in 
mutant strains, OMVs production also occurs 65.  Analyzing these vesicles is challenging, however, 
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sophisticated analytical tools have been recently developed such as proteomics. Several studies 
have shown that the bulk of OMVs consists of outer membrane, periplasmic, cytoplasmic and 
cytoplasmic membrane proteins 62, 66-67.  A few OMVs are bi-layered structures, with an inner 
membrane as well as an outer one; presumably, these layers correspond with the bacterial inner 
and outer membranes, respectively 68. Multiple OMV biogenesis models have been proposed, but 
details concerning OMV biogenesis remain unclear; OMVs containing outer membranes only 
predominate, yet, in a small percentage of OMVs sections of the bacterial inner membrane may 
become incorporated into the budding process that leads to the generation of OMVs.  
 
OMVs are known to play roles in bacterial pathogenesis; variousvirulence factors are often 
incorporated into OMVs and transported by these. VirD4, secreted via a type IV secretion system, 
is often found in OMVs of Helicobacter pylori; blood group antigen-binding adhesin (BabA) 
and sialic acid-binding adhesin (SabA) are molecules that facilitate the interaction with host 
epithelium and are also carried in OMVs 62, 69.  HtrA, a protease involving in misfolded-protein 
accumulation identified in OMVs secreted from both E. coli and H. pylori, and plays a roles in 
pathogenesis by disrupting E-cadherin cleavage 69-70.  Environmental stressors, such as 
temperature change and limited nutrients supply can trigger OMV upregulation in conjunction 
with stress related proteins, which become incorporated with the OMVs, altering OMV protein 
profiles 62. OMVs serve a protective role in bacterial survival, mediating biofilm formation and 
antibiotic resistance 71.  OMVs are also a potent contributor of bacterial aggregation and 
enhance bacterium-bacterium interactions regarding quorum sensing and communication 72-73.  
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1.3.3 Role in Immune System 
The immunogenicity prosperities of OMVs have been studied extensively in many bacterial strains; 
OMVs have been shown to interact with diverse host cells to modulate immune responses and 
protect bacteria from host immune attack. OMVs are secreted by both pathogenic and commensal 
bacteria during growth periods in a non-replicative vesicle form. Epithelial cells are the first 
defense line in the host, and are where OMVs typically translocate initially following secretion. 
OMVs collected from H. pylori can interact with gastric epithelium cells to promote dose-
dependent interleukin-8 (IL-8) response 74. Likewise, Pseudomonas aeruginosa OMVs engage 
in lung epithelial cells and stimulate IL-8 secretion 75. Klebsiella pneumoniae OMVs stimulate 
IL-1β and IL-8 production in laryngeal epithelial cells 66, 76. An in vivo study has reported that 
H. pylori OMVs containing peptidoglycans that can be recognized by nucleotide-binding 
oligomerization domain-containing protein 1 (NOD1) in the host. The binding of which 
presumably induces innate and adaptive immune responses 77.  
 
TLR4 is a well-studied pattern recognition receptor (PRR) that often interacts with OMVs. LPS 
presenting on OMVs from E. coli arouses TLR4 dependent immune responses 78. Another study 
shows that OMVs mediating tumor necrosis factor (TNF) tolerance in monocytes through TLR4 
79. In addition to colonizing surface epithelial cells, OMVs can induce physiological damage to 
epithelium, allowing OMV transported virulence factors to interact with cells in the submucosa80.  
After transit into underlying tissues, OMVs interact with multiple immune cells to induce pro-
inflammatory activity. N. meningitides OMVs activate neutrophils, triggering cytokines 
including TNFα and IL-1β; E. coli OMVs contain cytotoxic necrotizing factor type 1 that 
restrain antimicrobial activity and neutrophil chemotaxis 81-82. OMVs interact with 
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macrophages  cytokines, for example, N. meningitidis OMVs induce monocyte and macrophage 
production of IL-1β, IL-6 and other cytokines 83 (Table 1). Meanwhile, these interactions with 
macrophages also trigger adaptive immune responses, stimulating upregulation of HLA-DR, 
CD80, and CD86 83. OMVs are able to promote dendritic cells (DCs) maturation and foster B 
cell and T cell responses 84. When OMVs circulate to other body sites in addition to the primary 
infection area, they can modulate other host cells including platelets and endothelial cells 85-86. 
Overall, these immunogenic abilities make OMVs ideal components for vaccines and adjuvants.  
 
 
 
 	
Table 1  Role of OMVs in immune system		
					
 
 
 
   
Bacteria Function in immune system 
H. pylori Promote IL-8 response;  
target NOD1 and induce innate response 
P. aeruginosa Encourage IL-8 secretion 
E. coli Present LPS and stimulate TLR4 response; 
Restrain antimicrobial activity and chemotaxis of netrophil 
K. pneumoniae  Stimulate IL-1β and IL-8 
N. meningitides Stimulate neutrophil to produce cytokines; 
Inspire monocyte and macrophage to produce IL-1β, IL-6 and 
other cytokines  
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1.3.4 Vaccine Candidates and Application 
Stable, non-replicated nano-sized properties of OMVs give them great potential for vaccine design. 
The proteomic study by mass spectrometry and computational analysis classified components of 
OMVs from different strains; multiple molecules have been postulated as vaccine candidates.   
 
An OMV preparation developed against N. meningitides serogroup B is the first approved vaccine 
generated from the wild type strain 87-88. ProA and ProB are the two main prion antigens 
transported by OMVs, while other minor proteins have been used for cross-protection 89-90. For 
example, Bexsero® using OMVs with capsular polysaccharide combined with a recombinant 
protein have been developed and proven as a safe vaccine 91. OMVs from a genetically engineered 
strain with attenuated LPS toxicity and overexpressed PorA provide a safer and more effective 
vaccine approach 92. OMVs isolated from epidemic strains against serogroups A, W and X, which 
cause meningitis in Africa, have been examined under clinical trials for vaccine development 88.  
 
Bordetella pertussis is the major cause of whooping cough in both children and adults. Roberts et 
al. identified 43 proteins in the OMVs of B. pertussis. Among these, numerous major surface 
antigens such as adenylate cyclase-hemolysin, pertactin, and lipo-oligosaccharide were found 93. 
Significant immune and protective responses were observed in mice immunized with the above 93. 
Engineered OMVs collected from inactive B. pertussis carried multiple antigens including 
pertussis toxin and a lipid A 3-deacylase have been evaluated in an intranasal challenge model and 
were shown to induce protection 94. This study supports the speculation that OMVs from B. 
pertussis have strong potential as a candidate for vaccine against pertussis.  
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Other investigations of OMV-based vaccine approach against human diseases, including enteric 
disease and tuberculosis, have been developed in the past decade. OMVs extracted from V. cholera, 
Salmonella and Shigella, the main pathogens for enteric infection, are able to trigger extensive IgG 
and IgA level responses 88. LPS-modified OMVs collected from V. cholera and E. coli have the 
ability to elicit specific protective immune responses and have been explored as a heterologous 
vaccine delivery platform 95. OMVs from Mycobacteria have been verified as interacting with 
TLR2 to stimulate cytokine and chemokine response in a mouse model, which provides evidence 
as a vaccine candidate for eliciting active immune responses 96.  
 
Overall, OMVs are expected to become widely used as an advanced platform for safer and well-
mediated vaccines against diverse pathogenic and commensal bacterial strains associated with 
various human diseases.  
 
1.4 Vaccine Development  
The first vaccine was developed in Asia 1,000 years ago against the smallpox virus.  Later in the 
eighteenth century, Edward Jenner noticed milkmen infected with cowpox acquired the ability 
against smallpox infection. since then, vaccinology has changed and developed with the aim of 
generating vaccines that are both highly immunogenic and present few side effects. Two major 
methods have been established to enhance vaccine immunogenicity: attenuated pathogens and 
recombinant proteins. There are numerous dilemmas in both approaches. In the first one, 
immunogenicity may compromise for safety and tolerability; and the second approach is limited 
by side effects. Therefore, an integrated approach to design vaccine capable of mimicking 
properties of pathogens without causing disease is necessary.  
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Important factors include the size, geometry, kinetics and surface antigens97. The size of vaccine 
determines the available of uptake by antigen presenting cells (APCs), which is crucial for T cell 
response. It has been speculated antigens around 20-100nm in size (similar to pathogen size), are 
able to maximize the uptake capacity of APCs or transport into lymph vessels 97.  The geometry 
and the quantity of antigenic determinants of the vaccine is essential for B and T cell responses. 
Highly repetitive particle patterns similar to the spacing of pathogen coat proteins are crucial for 
triggering B cell responses 97-98. The surface pattern is significant in optimizing long-lived T helper 
cell responses. Additionally, subsequent boosters instead of single dose injection might prolong 
and enhance the protective efficacy.   
 
In summary, nanoparticle vaccines, such as OMVs, have proven themselves to be very useful in 
vaccine design. OMVs as a type of nanoparticle with the proper size between 20-200 nm and are 
not replicable, making them safe as a vaccine delivery platform. Furthermore, OMVs are isolated 
from cultures of pathogens, and therefore antigenically similar if not identical to the pathogen 
under consideration. These qualities allow OMV vaccine preparations  to mimic pathogen 
specifically and precisely, thus are able to elicit specific immune responses. OMVs will 
undoubtedly become the basis for a whole generation of upcoming vaccine designs.  
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CHAPTER TWO 
PROTEOMIC CHARACTERIZATION OF OUTER MEMBRANE VESICLES FROM 
GUT MUCOSA-DERIVED FUSOBACTERIUM NUCLEATUM 
 
Introduction  
Fusobacterium nucleatum is an opportunistic Gram-negative non-spore forming and obligate 
anaerobic bacterium with a fusiform rod shape and is a key component of plaque and a common 
resident of human oral cavity 1-3. It is a heterogeneous species and one of the most abundant 
organisms identified in endodontic infections 1, 3.  F. nucleatum is a primary contributor to many 
types of periodontal diseases 4-5. It is abundant in the oral cavity of patients with periodontitis and 
gingivitis, although it can also be detected in healthy people at lower levels 5-8. Chronic periodontal 
disease patients often show elevated IgG and IgA responses to F. nucleatum, whose bacterial load 
has been positively correlated with the progression of disease 5-6, 9. F. nucleatum can reduce the 
oxygen concentration in the microenvironment, thus facilitating the growth of other anaerobic 
bacteria, such as Porphyromonas gingivalis 10. These mixed anaerobic colonies form 
coaggregation units and play an essential role in cell surface attachment and plaque formation in 
the oral cavity 4, 11-13.   
 
Recent lines of evidence have suggested an oncogenic role of F. nucleatum in the development of 
colorectal tumors 14. The human gut contains a great variety of microbial species, some of which 
have long been suspected of being potentiators of colorectal cancer (CRC), the fourth most 
frequent cause of cancer death worldwide 15-16. More recently, studies have linked gut colonization 
with the oral cavity-resident bacterium, F. nucleatum, with CRC tumorigenesis and metastasis 17. 
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This association led many researchers to postulate that F. nucleatum is a contributor to intestinal 
carcinogenesis 18-19.  
 
In multiple studies, F. nucleatum abundance consistently increases comparing normal colon to 
adenoma and adenoma to CRC 18, 20-23. Higher CRC F. nucleatum levels are associated with 
increased WNT and NFKB signaling, production of IL17 and other cytokines, tumor associated 
myeloid cells, fewer tumor infiltrating T cells (TILs) and shorter survival24-25. In vitro, F. 
nucleatum co-culture with conventional CRC cell lines increases tumor promoting autophagy, 
TLR4 and RIG-1 signaling 21-23. The F. nucleatum adhesin FadA binds to CDH1 and promotes 
colonocyte WNT/proliferation 26; and the lectin Fap2 binds to and promotes adhesion to human 
TIGIT, which inhibits recruitment of tumor-infiltrating NK cells and lymphocytes 27. In Apc 
mutant mice, oral gavage with F. nucleatum increases small intestinal and colon adenomas (4). F. 
nucleatum levels in CRC are most strongly associated with right-sided location, mucinous 
adenocarcinomas and mismatch repair deficient CRC 18, 20, 24-25. 
 
 Many colorectal tumor tissue samples have been shown to have relatively heavy F. nucleatum 
bacterial loads compared with adjacent normal intestinal tissue sites 18, 28. One well-characterized 
virulence factors of F. nucleatum is the adhesion protein FadA, which facilitates bacterial 
attachment and invasion 26, 29. FadA promotes carcinogenesis via binding to an E-cadherin receptor, 
activating β-catenin and driving up expression of transcriptional factors, Wnt genes, inflammatory 
genes, and associated oncogenes 26.  Another associated virulence factor of F. nucleatum is lectin 
Fap2, a galactose adhesion protein, which binds Gal-GalNAc, facilitating localization and 
colonization of F. nucleatum in CRC cells 27.  Additionally, Fap2 suppresses T cell and natural 
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killer (NK) cell activities via inhibitory receptor TIGIT binding; this results in the impairment of 
T cell/NK cell activity, allowing cancerous tumors to effectively evade immune responses 21.  
 
The most commonly practiced prevention strategy for CRC is chemoprevention such as using 
aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) 30-31. However, long-term use of 
aspirin (or other NSAIDs) is associated with adverse effects including gastrointestinal (GI) 
bleeding. Safer alternatives for CRC prevention are urgently needed. Another potential approach 
to reduce F. nucleatum colonization is vaccination. Outer membrane vesicles (OMVs) have 
recently emerged as powerful vaccine delivery systems. OMVs are naturally secreted, bi-layered 
lipid membrane nanostructures produced by Gram-negative bacteria as metabolic byproducts 32.  
OMVs offer characteristics that are ideal for vaccine applications. For example, they contain much 
of the biological content of the parent bacterium, but without replicative or infectious capacity; are 
highly stable and highly immunogenic; and can interact with epithelial and immune cells in content 
dependent manner. In 2013, the European Medicines Agency (EMA) and US Food and Drug 
Administration (FDA) approved a vaccine containing OMV components for inoculation against 
infection by meningococcal serogroup B 33. The nanosized structure enables the uptake of OMVs 
by antigen presenting cells,  and facilitates efficient transport through lymphatic system 34. It is 
highly conceivable that similar OMV-based vaccines could be developed against F. nucleatum 
infection. While F. nucleatum OMVs have been shown to contain various antigenic elements, a 
comprehensive analysis of all the components found in OMVs generated by F. nucleatum has yet 
to be completed.    
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In this study, we isolated and purified OMVs from F. nucleatum subsp animalis 7_1 (EAVG_002) 
and biophysically and proteomically profiled the purified OMVs to explore potential development 
strategies for OMV-based F. nucleatum vaccines. The diameter and shape of OMVs were 
measured using transmission electron microscopy and dynamic light scattering. OMVs’ 
constituents and membrane fraction composition were analyzed by nano LC/MS/MS and 
characterized by bioinformatics tools. The results from our comprehensive analysis of F. 
nucleatum OMVs as reported below can serve as a firm foundation for further discoveries 
regarding their role in pathogenesis and anti-F. nucleatum vaccine development.  
 
Materials and Methods  
Bacterial strains and cultivation  
F. nucleatum subsp animalis 7_1 (EAVG_002) was kindly provided by Dr. Emma Allen-Vercoe 
(University of Guelph) 35. The strain was grown anaerobically (80% N2, 10%CO2, 10% H2) at 
37°C either on Fastidious Anaerobe Agar (Neogen) with 5% horse blood or in tryptic soy broth 
(Becton, Dickinson and Company) with 5 µg/mL hemin and 5 µg/mL menadione (Sigma-
Aldrich)35. The bacteria were harvested at OD600 0.7~0.9. A volume of each strain was mixed with 
an equal volume of glycerol and stored at -80 °C in cryogenic storage tubes for further use.  
 
OMVs isolation and purification  
The OMVs of F. nucleatum were collected from the supernatant of bacterial culture (200mL) 
according to the method described by Chutkan et al. with modifications36-37. The process flow 
chart is shown in Figure 2. Briefly, cells were spun down by centrifugation at 8500 x g for 15 min 
at 4°C (rotor JA-14, Beckman-Coulter), then the supernatant was vacuum filtered through a 0.22-
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µm membrane to remove any remaining bacteria. The OMVs were collected by ultracentrifuge at 
213,000 x g for 2hr at 4°C (rotor Type 50.2 Ti, Beckman-Coulter). The pelleted OMVs were 
suspended with sterile phosphate-buffered saline (PBS). The resuspended OMVs were purified by 
density gradient centrifugation with OptiPrep™ (60% iodixanl (w/v), Axis-Shield). The 
OptiPrep™ solution was diluted with 0.85% (w/v) NaCl containing 10mM Tricine-NaOH pH 7.4 
into 35%, 30%, 25%, 20% (v/v) OptiPrep™.  The 40% OptiPrep™ solution was prepared with 
suspended OMVs and layered 2mL at the bottom of an Ultra-Clear™ centrifuge tube (13.2 mL, 
Beckman Coulter).  The discontinuous gradients were loaded in 2 mL increments in degressive 
concentrations on top of the prior layer 36. Prepared tubes were centrifuged at 135,000x g for 16 
hr at 4°C (rotor SW 41 Ti, Beckman-Coulter). Each 1 mL fraction was carefully collected by pipet 
from top to bottom. A portion of each fraction was analyzed by 12% SDS-page, which displayed 
that the OMVs were mainly contained in fraction 25%~30% (data not shown). The OMV-
containing fractions were collected and pooled into an ultracentrifugation tube with 27 mL sterile 
PBS (at least 10-fold the sample volume) and ultracentrifuged at 200,500 x g for 2hr at 4°C (rotor 
Type 45 Ti, Beckman Coulter) to remove the OptiPrep™ solution. The purified OMVs were 
resuspended with sterile PBS and the aliquots were stored at -80°C for future use. 
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Figure 2  Flow chart of OMVs isolation and purification 
The overnight-cultured bacteria are spun down at low speed to exclude the whole bacteria. The 
supernatant is filtrated with 0.22 µm membrane to remove the debris. The filtrated media is 
ultracentrifuged at 213,000 x g for 2 hours 4 °C. The pellet containing OMVs is resuspend with 
PBS and further purified by gradient purification at 135,000 x g for 16 hours at 4 °C. The OMVs 
can be visualized and further collected by dilute with PBS and ultracentrifuge at 200,500 x g for 2 
hours 4 °C. The product was aliquoted and stored at – 80 °C. 
The figure is adapted from Klimentová et al. Microbiological Research (2015) 37.  
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Cellular fraction preparation  
The cellular fractions were obtained from the same culture as the OMV preparations, based on the 
protocol by Aguilera et al. with modifications 38. The harvested cells were washed with sterile PBS 
three times and suspended in 20 mM Tris–HCl, pH 8.0 with 20% sucrose and 1mM EDTA, then 
mildly shaken at room temperature for 10 min. The solution was spun at 8500 x g for 15 min at 
4°C (rotor JA-14, Beckman-Coulter), immediately suspended in ice-cold sterile water (200mL), 
and gently shaken at 4°C for 10 min. The supernatant with periplasmic components was collected 
by centrifugation (8500 x g for 15 min at 4°C). The cell pellets were suspended in 20 mM Tris-
HCl, pH 8.0 (25mL) and disrupted by sonication. The suspension was centrifuged at 8500 x g for 
15 min at 4°C; the supernatant was ultracentrifuged at 120,000 x g for 1 hr at 4°C. The pellet was 
dissolved in 20 mM Tris–HCl, pH 8.0 containing 2% N-lauryl sarcosyl (Sigma-Aldrich) (5 mL) 
for 30 min at 37ºC.  The supernatant consisting of inner membrane portion and the pellet contained 
outer membrane proteins was suspended in 20 mM Tris–HCl buffer (1 mL). The periplasmic 
fraction was (v/v) concentrated 100:1 (Millipore) and all fractions were filtered using a 0.45-µm 
PVDF membrane (Millipore) to remove remaining cells. A portion (12.5 µL) of each sample was 
analyzed by 12% SDS-PAGE and the rest was stored at -80°C.  
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*PP- periplasmic fraction 
CP- cytoplasmic fraction 
IM – inner membrane fraction 
OM- outer membrane fraction 
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Figure 3  The flow chart of prepare cellular fractions 
The harvested cells were washed three times with sterile PBS and suspended in 20 mM Tris–HCl, 
pH 8.0 with 20% sucrose and 1mM EDTA. After mildly shaken at room temperature for 10 min, 
the solution was spun at 8500 x g for 15 min at 4°C (rotor JA-14, Beckman-Coulter). Then 
immediately suspended the pellet in ice-cold sterile water, and gently shaken at 4°C for 10 min. 
The supernatant with periplasmic components was collected by centrifugation (8500 x g for 15 
min at 4°C). The cell pellets were suspended in 20 mM Tris-HCl, pH 8.0 (25mL) and disrupted by 
sonication. The suspension was centrifuged at 8500 x g for 15 min at 4°C to remove the whole 
cells and debris; the supernatant was ultracentrifuged at 120,000 x g for 1 hr at 4°C. The pellet was 
dissolved in 20 mM Tris–HCl, pH 8.0 containing 2% N-lauryl sarcosyl (Sigma-Aldrich) for 30 
min at 37ºC.  The supernatant consisting of inner membrane portion and the pellet contained outer 
membrane proteins was suspended in 20 mM Tris–HCl buffer.  
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Dynamic light scattering (DLS) 
The size distribution of OMVs in sterile PBS was determined with DLS using a Malvern Nano ZS 
Zetasizer (Malvern Panalytical). Triplicate measurements of 100 ng/µL OMVs samples in 1.0 mL 
were loaded into disposable sizing cuvettes at 25°C, and the system was assigned with 1.330 
dispersant refractive index and 0.8882 viscosity. The average diameter (Z-average) of OMVs were 
collected and analyzed with the Zetasizer software.  
 
Transmission electron microscopy (TEM) 
Samples were negative stained with 1.5% aqueous Uranyl Acetate on 300 mesh carbon coated 
copper TEM grids. The images were acquired using a Thermo-Fisher Tecnai Spirit Twin STEM 
equipped with a SIS MegaView III camera in TEM mode at 120kV.  
 
In-gel trypsin digestion of SDS gel bands 
 The protein bands from a 12% SDS-PAGE gel (2 to 4 gel slices for each of the 6 samples) were 
cut into ~1 mm slices and subjected to in-gel digestion followed by extraction of the tryptic peptide 
as reported previously 39. The excised gel pieces were washed consecutively in 200 µL distilled 
water, 100 mM ammonium bicarbonate (Ambic)/acetonitrile (1:1) and acetonitrile. The gel pieces 
were reduced with 70 µL of 10 mM DTT in 100 mM Ambic for 1 hr at 56°C, alkylated with 100 
µL of 55 mM Iodoacetamide in 100 mM Ambic at room temperature in the dark for 1 hr.  After 
washing gel slices as described above, the gel slices were dried and rehydrated with 50 µL trypsin 
(Promega, Madison, WI) in 50 mM Ambic, 10% ACN (20 ng/µL) at 37°C for 16 hrs. The digested 
peptides were extracted twice with 70 µl of 50% acetonitrile, 5% FA and once with 70 µl of 90% 
acetonitrile, 5% FA. Extracts from each sample were combined and lyophilized.  
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Protein Identification by nano LC/MS/MS Analysis 
In-gel tryptic digests were reconstituted in 20 µL of 0.5% FA for nano LC-ESI-MS/MS analysis, 
which was carried out using an Orbitrap FusionTM TribridTM (Thermo-Fisher Scientific, San Jose, 
CA) mass spectrometer equipped with a nanospray Flex Ion Source, and coupled with a Dionex 
UltiMate3000RSLCnano system (Thermo, Sunnyvale, CA) 40-41.  Gel extracted peptide samples 
(5-15 µL) were injected onto a PepMap C-18 RP nano trapping column (5 µm, 100 µm i.d x 20 
mm) at 20 µL/min flow rate for rapid sample loading and then separated on a PepMap C-18 RP 
nano column (2 µm, 75 µm x 25 cm) at 35°C. The tryptic peptides were eluted in a 120 min 
gradient of 5% to 38% acetonitrile (ACN) in 0.1% formic acid solution at 300 nL/min., followed 
by a 7 min ramping to 90% ACN-0.1% FA and an 8 min hold at 90% ACN-0.1% FA. The column 
was re-equilibrated with 0.1% FA for 25 min prior to the next run.  The Orbitrap Fusion was 
operated in positive ion mode with spray voltage set at 1.6 kV and source temperature at 275°C. 
External calibrations for FT, IT and quadrupole mass analyzers were performed. In data-dependent 
acquisition (DDA) analysis, the instrument was operated using FT mass analyzer in MS scan to 
select precursor ions followed by 3-second “Top Speed” data-dependent CID ion trap MS/MS 
scans at 1.6 m/z quadrupole isolation for precursor peptides with multiple charged ions above a 
threshold ion count of 10,000 and normalized collision energy of 30%.  MS survey scans at a 
resolving power of 120,000 (fwhm at m/z 200) for the mass range of m/z 375-1575.  Dynamic 
exclusion parameters were set at 40 s of exclusion duration with ±10 ppm exclusion mass width. 
All data were acquired under Xcalibur 3.0 operation software (Thermo-Fisher Scientific).  
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Data analysis 
The DDA raw files for CID MS/MS were subjected to database searches using Proteome 
Discoverer (PD) 2.2 software (Thermo Fisher Scientific, Bremen, Germany) with the Sequest HT 
algorithm. The PD 2.2 processing workflow containing an additional node of Minora Feature 
Detector for precursor ion-based quantification was used for protein identification and relative 
quantitation analysis. The database search was conducted against a combined database containing 
Fusobacterium nucleatum RefSeq database 2416 entries downloaded from UniProt.  Two-missed 
trypsin cleavage sites were allowed.  The peptide precursor tolerance was set to 10 ppm and 
fragment ion tolerance was set to 0.6 Da. Variable modification of methionine oxidation, N-
terminal acetylation and deamidation of asparagine/glutamine and fixed modification of cysteine 
carbamidomethylation, were set for the database search.  Only high confidence peptides defined 
by Sequest HT with a 1% FDR by Percolator were considered for the peptide identification. The 
final protein IDs contained protein groups that were filtered with at least 2 peptides per protein.   
 
Bioinformatics analysis  
Sequence of each protein was acquired from both UniProt database (http://www.uniprot.org/) of 
F. nucleatum subsp. animalis 7-1 and NCBI (F. nucleatum RefSeq20170725) Protein database 
(https://www.ncbi.nlm.nih.gov/protein/) 42-43. Outer membrane protein beta-barrels were predicted 
by PRED-TMBB2 (http://www.compgen.org/tools/PRED-TMBB2) 44. Subcellular localization, 
adhesion affinity levels, and transmembrane helices of proteins were obtained from Vaxign 
(http://www.violinet.org/vaxign/) 45-49. Protein localization was predicted by Cello2go 
(http://cello.life.nctu.edu.tw/cello2go/), and signal peptides, including lipoproteins, were predicted 
by LipoP 1.0 Server (http://www.cbs.dtu.dk/services/LipoP/) 50-51. Putative function domains of 
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each protein was generated from InterPro  (https://www.ebi.ac.uk/interpro/) 52.  Non-classical 
protein secretion was anticipated by SecretomeP 2.0 Server 
(http://www.cbs.dtu.dk/services/SecretomeP/) for proteins without predicted signal peptide 53. All 
of the proteins with predicted signal peptides contain exposed antigen peptides predicted by 
EMBOSS (http://www.bioinformatics.nl/cgi-bin/emboss/antigenic) with EMBOSS Motif output 
report format and six minimum lengths of regions for the various antigenic sites 54-56. Antigenic 
B-cell epitopes were predicted using BCPREDS: B-cell epitope prediction server 
(http://ailab.ist.psu.edu/bcpred/predict.html) 57. In this application, two methods-BCPred (fixed 
length epitope prediction) and FBCPred (Flexible length epitope prediction) with assigned length 
12, 75% specificity and a prediction score larger than 0.9 were selected and shown in the table. To 
identify T-cell epitopes Vaxitop (http://www.violinet.org/vaxign/vaxitop/index.php) was applied 
with P-value cut-off 0.05 for all HLA-A2 and HLA-A3 alleles; the classes selection were based 
on previous publications that they showed overexpressed patterns in colon tumor tissues 45-46, 58-59. 
Metabolic pathways were classified with KEGG pathway database 
(http://www.genome.jp/kegg/pathway.html) 60. Functional groups were classified by EggNOG 
4.5.1 (http://eggnogdb.embl.de/#/app/home) 61. Cargo sorting to the OMV in F.nucleatum was 
plotted by ggplot2 package with R studio 62.  
 
Results 
Production and purity of OMVs from F. nucleatum subsp animalis 7_1 (EAVG_002) 
The OMVs collected from the supernatant of F. nucleatum subsp animalis 7_1 (EAVG_002) broth 
were verified by transmission electron microscopy (Figure 4) and dynamic light scattering (Figure 
5).  The OMVs appear varied ranging in size from 40 to 110 nm with spherical shapes; the typical 
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diameter was around 79 nm (Figure 5).  Duplicate OMV preparations and cellular fractions from 
F. nucleatum were separated on an SDS-PAGE gel.  Each gel-lane was excised into multiple 
sections (Figure 6) and analyzed by mass spectrometer. Among these, 157 proteins were identified 
from the first duplication and 190 proteins were identified from the second duplication, with 98 
overlapping proteins identified in both duplications (Figure 7, Table 2). Purity of OMVs was 
estimated by comparing these to abundant proteins in the cytosol and inner membrane fractions. 
Abundant cytosol proteins were assessed by high number of peptide spectrum matches (PSMs) 
and by those lacking predicted signal peptides. Among the top 30 cytosol proteins with highest 
PSMs, only one (A0A140PU88) was identified as one of the 98 OMV proteins (Figure 8). Five of 
the top 30 inner membrane proteins were also recognized on OMVs, which are WP_008700001.1, 
WP_008701980.1, WP_016361171.1, A0A140PRA0, and WP_008701946.1 (Figure 9). All five 
proteins were detected in the periplasmic and outer membrane fractions, suggesting these proteins 
may break free from the inner membrane, migrate to other fractions and ultimately bind to OMVs 
(Figure 9).  Three of these five proteins were classified as autotransporters, which might explain 
their appearance in multiple fractions. The near absence of cytoplasmic proteins in OMVs implies 
that the level of debris contamination was negligible.  
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Figure 4  TEM image of F.nucleatum OMVs   
A TEM image of OMVs in size varied from 40 to 100 nm with spherical shape. Majority has the 
size around 40. 
  
	 39	
 
 
 
 
Figure 5  The DLS measurement of OMV 
The average size of OMV is 78. 74 nm, 93.6% intensity is identified at size 94.38 nm. The 
measurement is with good quality. 
  
	 40	
 
 
 
 
Figure 6  SDS-PAGE gel excision  
SDS-PAGE of F.nucleatum fractions and OMVs used for proteome analysis and duplicated 
identified proteins from OMVs. SDS-PAGE of subcellular fraction for periplasm (PP), cytoplasm 
(CP), inner membrane (IM), outer membrane (OM) and duplication of OMV1&2. The gel excision 
was as shown.  
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Figure 7  Venn diagram of the duplication OMVs 
98 overlapping proteins were identified from the two batches of OMVs. 
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Table 2  98 Identified Proteins on OMVs 	
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Table 2. 98 identified proteins in both OMV replications. 
a Average molar % (by abundance) of each protein calculated from replicated OMV samples. b 
Molar% of outer membrane fraction for identified protein. c Prediction of transmembrane segments 
by PRED-TMBB with cut-off 0.43. d Predicted adhesion probability of each protein.  * The protein 
had been identified both from UniProt and NCBI databases. # The protein had been identified both 
on outer membrane and periplasm fraction with a molar% ratio smaller than 0.4. +The proteins 
classified as cytosol protein and without signal peptide were predicted as non-classically secreted 
protein by recommend threshold 0.5. 
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Figure 8  Purity of OMVs from F. nucleatum compare with cytosol fraction 
The top 30 PSMs score proteins known in the cytoplasm fraction compare with the score obtain 
from all other fractions. Only protein A0A140PU88 was found in both OMVs. A0A140PSZ7, 
A0A140PQ10, and A0A140PU12 were identified in OMV1 only with small amount. 
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Figure 9  Purity of OMVs from F. nucleatum compare with periplasmic fraction 
The top 30 proteins identified from the inner membrane fraction compare with score obtain from 
other fractions. Five proteins (WP_008900001.1, WP_008701980.1, WP_016361171.1, 
A0A140PRA0 and WP_008701946.1) was recognized in the OMV, periplasmic and outer 
membrane fractions.  
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Topology prediction of the proteins to OMVs  
Among the 98 overlapping proteins of OMVs, 52 were commonly found in all subcellular fractions 
(Figure 10), 60 were predicted with signal peptides, including 31 with a type II signal peptide 
deemed likely to be lipoproteins (Table 2). Both Vaxign, which used the open-source database 
from PSORTb (v. 2.0), and Cello2go predicted the subcellular localization of identified proteins. 
Vaxign predicted the subcellular location for the 98 common proteins individually (Table 2, Figure 
11).  Many OMV related proteins were present in multiple subcellular fractions.   Distribution was 
expressed as a percent of total abundance of a given protein (or a given class of proteins) found in 
a specific fraction. The calculation is as follow:  
           Individual Protein Abundance  
Abundance % = --------------------------------------------------- X 100% 
   Total Protein Abundance  
 
Although a variety of cytoplasmic proteins were predicted, outer membrane constituted the 
majority of the OMV in mass (Figure 12). Outer membrane proteins were the most abundant 
component of OMVs, which made up 72% of the total protein, whereas 17% consisted of proteins 
having unknown subcellular localization traits and 6% were determined to be periplasmic proteins. 
Cytoplasmic proteins represented only 5% of proteins enriched in the OMVs (Figure 12). This 
distribution pattern was virtually identical in separately run OMV1 and OMV2 topological 
analysis. Outer membrane proteins were the major ingredients of each OMV batch sample (not 
shown here), although the OMVs were found to contain a variety of protein localization classes. 
To further predict the localization sites of the OMV proteins to the vesicle membrane and lumen, 
relative abundance of individual proteins in the outer membrane and periplasm fractions (M/P) 
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was compared for the consistently identified OMV proteins with predicted signal peptide. Eighteen 
of the 60 proteins with predicted signal peptides were not present in the periplasmic fraction and 
only 9 of the proteins with signal peptide were abundantly (M/P ratio < 0.4) detected in the 
periplasm fraction. These findings indicated that the OMVs of F. nucleatum were almost solely 
derived from the outer membrane, although other proteins from subcellular fractions were present 
in small quantities in the OMVs.   
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Figure 10  Venn diagram of proteins from all subcellular fractions  
52 overlapping proteins are commonly identified in all subcellular fractions and OMVs. 72 
proteins appeared both in OMV and outer membrane fraction, 73 proteins found both in OMV and 
inner membrane fraction, 72 overlapping proteins found in OMV and periplasmic fraction, and 69 
are shown both in OMV and cytoplasmic fraction.   
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Figure 11  Topology analysis of OMV proteins based on proteins types 
Subcellular location predication for 98 proteins on OMVs. 42% proteins are predicated as 
cytoplasmic protein, 35% are located in multiple fractions.  15% proteins are predicted as outer 
membrane proteins following with 7% predicted periplasmic proteins. Extracellular proteins only 
own 1%.  
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Figure 12 Topology analysis of OMV proteins based on protein abundance 
Average mass abundance% from OMV1 and OMV2 for subcellular localization prediction. Outer 
membrane proteins were the most abundant component of OMVs, which took up 72%, following 
with 17% unknown location proteins and 6% periplasmic proteins. Cytoplasmic proteins only 
contained 5% richness in OMVs 
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Cargo sorting  
By comparing the abundance of proteins from OMVs and outer membrane fractions, the relative 
enrichment of commonly detected proteins were estimated. FadA protein was found to be 
incorporated into the OMVs more than in the outer membrane fraction, while some of the 
autotransporter (AT) proteins were maintained in the outer membrane (Figure 13). Autotransporter 
proteins were highly present in the F. nucleatum OMVs and are also major composition of F. 
nucleatum outer membrane, which appear to occupy over half of the total mass of OMV.  A single 
autotransporter protein (WP_016361171.1), with type II signal peptide and highest OMV/M ratio, 
was the premier component in both OMV replications, with an adhesion probability of 0.546 and 
predicted transmembrane β-barrel (Table 2).  Although other autotransporter proteins appear at 
higher concentrations in the membrane fraction than in the OMVs, these proteins were predicted 
to display high adhesion probability for components of both cell fractions (>0.51) (Figure 13).  
Two YadA-like proteins were present in both OMVs and outer membrane fractions with mid to 
high adhesion probability (0.482 and 0.642).  Numerous secretion proteins were predicted as 
highly likely adhesion proteins (square and triangle with lighter blue, Figure 13). The proportion 
of several identified non-secretion proteins were negligible; in contrast, some secretion proteins 
such as the Bacterial surface antigen protein (WP_023038391.1) and MORN protein 
(WP_008692599.1 and WP_008702680.1) were recognized only in OMVs (Figure 13). Overall, 
the secretion proteins were the major component of the F. nucleatum OMVs; the autotransporter 
proteins quantitatively constituted the majority of those incorporated into the OMVs and all the 
possible adhesion proteins were secretory (with predicted signal peptides).  
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Figure 13  Cargo sorting to the OMV in F. nucleatum  
The average protein mol% obtained from the OMV fractions compared to the mol% from outer 
membrane fraction. Proteins presented above the dashed line are relatively enriched in OMVs, 
oppositely, proteins below the trend line are deficient. The data for the figure can be found in Table 
2. 
 
  
	 56	
Identification of Antigenic Proteins from OMVs  
Reverse vaccinology was applied to investigate the potential for OMV-based vaccine development. 
In this approach, antigenicity of key targets such as exposed antigenic peptides, B-cell and T-cell 
epitopes was predicted using in silico analytical programs. The exposed antigen peptides for 16 
predicted outer membrane and extracellular proteins contained in OMVs were forecasted by 
EMBOSS. A number of antigenic peptides (from 6 to 83) were predicted on each protein; an 
autotransporter protein (WP_008701556.1) was found to contain 83 anticipated antigenic 
sequences.  This autotransporter was predicted as having multiple highly immunogenic epitopes 
within (Table 2, Table 3). B-cell epitope screening for selected outer membrane and extracellular 
proteins was achieved by BCPREDS. Non-overlapping epitopes were reported by both fixed 
(BCPred) and flexible (FBCPred) length prediction methods (Table 4). B-cell epitopes were 
successfully identified on all 16 proteins; the autotransporter proteins, WP_008701556.1 and 
WP_008701556.1 contained more antigenic epitopes than other fourteen proteins. T-cell epitopes 
of the top five most highly antigenic abundant proteins were predicted by Vaxitop, a vaccine 
epitope prediction system developed at the University of Michigan Medical School, to investigate 
the potential immunogenicity of F. nucleatum OMVs 46. The p-value cut off was assigned as 0.05 
for balanced binding probability and specificity. The T-cell epitopes against HLA-A2, HLA-A3 
and HLA-DRB1*0401 alleles were predicted according to the previous study on tumor antigens 
recognized by T-cells 58-59. The length of peptides against HLA-A2 ranged from 9 to 11, while for 
HLA-A3 the length was consistent at 9 residues.  Among the five selected proteins, the 
autotransporter protein (WP_008701980.1) had the highest number of predicted T-cell epitopes 
followed by another autotransporter protein (WP_016361171.1) with 188 and 63 HLA-A2 
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peptides, respectively (Table 5). Likewise, the autotransporter proteins had the higher number of 
identified HLA-A3 and HLA-DRB1*0401 epitopes than other proteins.  
 
Table 3  Antigenic Sequence Prediction  
Accession Hit 
Count 
Sequence Residues Scor
e 
A0A140PNL7 7	 IIASCMLALSLVGCTGF	ANAVAQYLIAQGVSSSRI	LIGAAVGSLVG	NALVINLPGGVTFAS	GAAVGALAGQI	SGFYSALNGIAQSLN	QGTQAQVK	
6->22	161->178	56->66	96->110	37->47	117->131	85->92		
1.178	1.156	1.147	1.134	1.109	1.066	1.039	
A0A140PP98 6	 KLYAVLLLALLVTACSS	LEDIIVF	NLELSVKRA	LILSMPELILFDFDKYIVKDK	KPSLSTLAKA	KDFLISRG	
4->20	49->55	124->132	69->89	91->100	136->143		
1.242	1.106	1.098	1.082	1.080	1.072		
A0A140PUD9 10	 LALVLGSLLVVGSVASAKEVMPAPTP	PEKVVEYVEKPVIVYRDR	SYELYMLPTFQVSYKPTDFVKLYAAAG	YTWHQYKVIAN	YYGALEAYLYQHTPL	AEASVLFDFADYL	SVDVQYR	TLDVRVR	EYTLPLGFS	SSKVKAT		
4->29	31->48	316->342	298->308	265->279	164->176	59->65	106->112	230->238	142->148		
1.219	1.164	1.135	1.116	1.114	1.108	1.099	1.097	1.086	1.060		
WP_008691343
.1 
 
19	 KLSILIVAGILVGCA		NIAVVAKY											VEEVPVDEGKVISK								AIILRVAKL												SFRSVYQGQYILSTY													EVNYLFLKYA		KVEVTKYLRLLKQ	KSEVLTK													KEVYDVIMQ													EYLSIVKGN										KSALQEYVGHK											NEVVRDKIKAVIDGT													MHEALAGV											TVGLGETLIFPL										ENAVTLY												DIFVPSE													EIYYNIASSYAK												IKLTAS													
4->18			157->164	48->61		243->251	133->147		205->214	392->404	414->420																			169->177																		70->78				271->281																	304->318		223->230		95->106																						187->193																		255->261		377->388																						112->117																
1.180	1.162	1.152	1.134	1.131	1.130	1.124	1.115	1.112	1.109	1.105	1.090	1.084	1.083	1.075	1.071	1.070	1.054	
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SIKKVEDS								 82->89		 1.051	
WP_008700150
.1 
 
14	 ILFIILCLFLISCSNL													VGTIHYFLCMRG												NVELFQIYIAS											VQNVELTFK												AYALEIIDYVI				YITLAEV												KPIITVFNF		VRNTVKNVK		SIGYSVSNGIELFIE												IELYSS									YLRSAQNLYYKADKIYSRYQ													QKYVSNY												IFEYYKK												QRKVAEK		
4->19			388->399																		87->97																	32->40															144->154																			193->199																370->378																412->420	324->338																													175->180	208->227																			281->287																67->73																	445->451		
1.226	1.154	1.129	1.117	1.116	1.110	1.097	1.088	1.0871.076	1.063	1.063	1.053	1.052	
WP_008700266
.1 
 
19	 SVSLKLIIFSFLLVSSSIAYSAAPTI		KQSVAVGLSYY									ESSVVLGHGSSVSESEVVSVGT													PQYVVQNEVKRLTV									KQLYQVAKA												GFTVKLG													EVNHKHLLIN										KDEVNHVGSLSAALAGLHPMQ													YSSAVGYE													QNSVALG													DIDVAAWKAKLGVGSGGVDLTAY													SNEVSVGSA						VSTVDSSAF									PTQVMAALGHY						KHSSAVG												IVNVREA													DGDVSAT													DPNVVTGN											SAGVAIG												
4->29																							612->622																			307->328															665->678																		354->362																		648->654															258->267																	573->593		93->100			497->503															366->388																																	511->519																			117->125																599->609		77->83				335->341																530->536	460->467	630->636		
1.176	1.161	1.149	1.136	1.124	1.117	1.114	1.112	1.095	1.093	1.0921.091	1.082	1.081	1.077	1.069	1.064	1.062	1.060	
WP_008700372
.1 
 
13	 SVSLKLIIFSFLLVAGSVAYSAPDF													KQSVAVGLSYY												YNEVPQYAIQDEVKRL													GFTVKLG												EVNHVGSLSAALAGLHPMQ													KVFDYD													SNEVSVGSA												VGTVNTV													SSTVGLYNKA										ASGVYSSAF								PTQVMAALGH												KAKVDSQ											SAGVAIG		
4->28	419->429																			468->483																			455->461															382->400																	261->266																	318->326																			221->227																190->199																73->81																		406->415																			498->504															437->443		
1.176	1.161	1.122	1.117	1.112	1.097	1.091	1.088	1.086	1.085	1.081	1.062	1.060	
WP_008701093
.1 
 
11	 KTILFSLILIFTFVSCSTLHTVVSKRNLDVQ												AKYWLQANILKVDKVNL												TVFVQIR										AGAAIGTLADALVDDT								LGKVIA													AIPLLED		YAMVTDILIT									STRVLSTA													
6->36																		91->107	54->60	143->158																						231->236	223->229															160->169																			206->213															
1.165	1.128	1.115	1.112	1.092	1.092	1.089	1.086	
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ITNVLTSK									IGGVLGA										DAALGA	 73->80																			122->128																115->120		 1.074	1.067	1.049	
WP_008701556
.1 
 
83	 KGLVHDVLVSYKKSGYHFIQD		EKVLVVKTF													AYGVVYLH		NGKVVPPTK																					QIKLLPAVGSIGT		RKYLVVNEI													AKGVYLVGN													LTTLVGVA													RGGVGLR													YTPVLGASIL										TSRVITVPQA		NYIPYSLIESNLK												IIEVEVSAGVKPR												RVLLLANGT												SIKYSLGMAILFLMLGVSAFS													PILLAQA												YKNYSSIISYVMG										NSLVRLERV		IVGLYGYQ													THGVNFTSSIVNLLSSN																												IGAVGAV													SDGVTYIRVK																			NLNLLSPKTKVDLIFGI																												SYKYYFGT													TNAAVPNPDYLSVSPG																										YANVQQRVQ													IRPYGALKVE												AFYYKL		GLIQLLGEH											DQVVKSP													GARLELIQLT																				QIYSASLTWI																			NIYVGAS													KNLHPVIKN													SVGLFSSQ													QSSIVNEK																			NQVVLG													GMYLDQH													IAPIQNV		YGIYSSGSVINY																						IGMYVDTS													VDIVSE													NVAYKFSKL													NAKVIQIGEKILKPY																										RIPPLPDF													PLKLLGK													EQVAIA		RGSVENLQIKLQKS		FGLVNI												QAKIGLFKSK																			GDIFVGYN													IKLIGAR													
502->522																		232->240																		1867->1874																	1605->1613																			1530->1542																	1944->1952															1300->1308																2036->2043																		2110->2116																			246->255																			261->270																			994->1006																	189->201																			956->964															21->41																										1794->1800																	340->352																				648->656	1255->1262																316->332																							1512->1518																819->828		1669->1685																										2026->2033															1616->1631																									1809->1817																			1982->1991																		918->923	1191->1199															97->103																	84->93																			1719->1728	1416->1422																	460->468																832->839																	1027->1034														1343->1348														1490->1496																		275->281																1377->1388			1652->1659																			638->643													1312->1320																	1692->1706																	220->227															551->557																1042->1047																61->74																						1327->1332															1910->1919															1933->1940														1481->1487		
1.231	1.190	1.188	1.1591.156	1.155	1.149	1.1461.1441.141	1.139	1.136	1.136	1.135	1.132	1.127	1.126	1.123	1.122	1.1191.113	1.113	1.1101.109	1.1081.1071.1041.103	1.100	1.097	1.097	1.095	1.094	1.094	1.091	1.091	1.089	1.0881.087	1.087	1.0841.083	1.082	1.081	1.080	1.078	1.078	1.077	1.077	1.076	1.076	1.075	
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SGALSSLAGKL																					KITVGDSGIGVYSSK																										IGIYYS													SKYYTYRIG													RIVLGNA													SQLITAH													KVKLFRT													KSIFRIY													SNAKVIAEE													NQVFQKL													RYGVEAL													GSLIHF																							DFLFYG													NDYLSIKP													AGIVDYK													AGDLKIG													DKVSLT																						YELIAT													DLQLAEE																							LKNILSS													INAVANK																							GMVFYN																							AKIPYTN					IEVIGKKS		KISVGKK													DRVVKN													NNVLFT													PTVKID													KTVVDE													RSIAKRF													KEFKYL	
977->987	1270->1284																								1129->1134															1957->1965																			1218->1224																	680->686		794->800														604->610																		851->859	1780->1786		1769->1775		411->416																		770->775														2012->2019																	1858->1864																1290->1296													1057->1062															583->588															181->187																			1157->1163																862->868	561->566														1744->1750														432->439																		1091->1097																	1408->1413																	877->882																	1589->1594														1580->1585														13->19															1825->1830		
1.075	1.0751.075	1.0731.073	1.072	1.072	1.072	1.067	1.066	1.065	1.064	1.063	1.062	1.061	1.060	1.059	1.057	1.055	1.055	1.054	1.053	1.050	1.049	1.042	1.040	1.038	1.035	1.033	1.022	1.020	
WP_008702403
.1 
 
46	 IRKVVVSQV																							MEKLIYYKLV													LFRVILLDSQ		YLIISLLASYSIVFAG														VAKIYFLE		KAALYLIEI													STKVYLNRV													YNQSIYHIFAINY																							LGIVYYNLK													LFTKLYAVK													YLSLAQDE													VSYLRASAIYR																				KVRFYLEK																												AASLYKEVY												FQKVLASGDQ																				YGRLFAVSP													YYSAQYYAAK													KTFFAVAQDFL												EYILYRLG													IEKYIAELP													KDVYLYTGD													IITLKLQKK													VISSLMSTLLEQK												EQAYYKYIMTLS											
359->367																		898->907																			406->415																4->19																63->70																236->244																			539->547															332->344																				168->176															880->888																	496->503															200->210																253->260															633->641																		527->536																393->401	759->768																128->138																				823->830																	744->752																			441->449															731->739																476->488																651->662																	
1.213	1.184	1.178	1.175	1.147	1.140	1.128	1.125	1.122	1.113	1.110	1.108	1.107	1.107	1.106	1.105	1.105	1.105	1.103	1.099	1.097	1.094	1.092	1.092	
	 61	
MALTDYKAVYSK											PKAVKEYETLLQYDKYKAY													GYEVYGKF		NYFLAE													GDLYVTK													YASYLARANA		QIYKTYLNQ													SVNYLKGI																			KLIYGEAYSLYKK																							KIGLSYFRLG													ARSYYSKI													EAVQAGEQYLSKI													KKFQSL													IRIIANSAYQVGNY		LKAAEIY											KAIYWLSEF													AKKYYGTYAT												KFLQKY													MKVYPN													MFYLRE											IKYFEE													KKLYDEL	
841->852																					771->789																									611->618		549->554														275->281															96->105																462->470	505->512																	301->313																	585->594																		599->606																		558->570																								321->326		373->386																				862->868																180->188																807->816																				45->50																678->683																		114->119																	218->223																915->921		
1.092	1.0901.087	1.085	1.085	1.084	1.083	1.075	1.073	1.073	1.070	1.0681.068	1.068	1.067	1.066	1.066	1.063	1.060	1.044	1.041	1.034	
WP_016361171
.1 
 
41	 IALASILFVSCG												GSGVKVAILDANFVNAVRS													GEEVLEVVRDLEY							KMLSAYVELG													KLQAYVTQA													MVGVSLYGKQDLPYGFY													NVEVKDGKVVATL													SVKVLGKI													LPLPFAKVHSG													EVWFSVLGSA												VAAILPTQEVYEA													SGTLVLNPKAIVGYDVDNF		EITPVFGVYGNVDFR													GSKVIGGTLEIHQVHASPITVG													GSSYAAPKVTRAAALVYDK													NGTVSVLSNGY												TLGVALNYSYAK													LKASLYTA												GGDYVAYA													LTDVYTDVEII													ADSVFSAGLQ													LMGATVQS													AGRLGLSHISSK													WISVIGA													SVEAGLPYFD												IYASAQALTFS													HPLVPRR													SNFLVGARAE													LGTLHL													TPSVPKPS													GSSVKQKFYGVK													VDKLSSA													KTILGSVGWDYTYV													
13->24																				103->121																		184->196																			941->950																		1007->1015															890->906																	706->718																							654->661																	288->298																		825->834																	238->250																584->602																									1057->1071	561->582																								428->446																										665->675																					865->876																			79->86															636->643																			149->159																			1078->1087																			764->771															908->919			348->354	332->341																	788->798																	139->145															991->1000																		547->552																43->50	1031->1042																		382->388	216->229	
1.187	1.148	1.141	1.139	1.138	1.134	1.1331.129	1.127	1.127	1.127	1.1261.124	1.1231.1231.120	1.115	1.104	1.103	1.101	1.0981.098	1.094	1.093	1.092	1.090	1.088	1.086	1.078	1.076	1.0751.074	1.073	
	 62	
LMIPYFRD													YWSIAADAYGVD													KATLPAGKT													FTPFIGYSQDY													NQSVKIFNQ													FPTVTNP													AENVEKVFED		SSGIKVK																								
303->310																			394->405																				521->529	956->966																		257->265																		62->68																	739->748																			615->621		
1.072	1.068	1.066	1.053	1.051	1.051	1.051	1.042	
WP_016361319
.1 
 
17	 LLLLLAILSSGVYASSIDHIQTYSPDYLSNQ													RRDLPAILSVGASYK													VSGVDVLTDLAQFKPLGIY												TLAITASVAHFIY													TKFQQRVSGLVKDGLVGDI													SFSIAGRVVHGSR		GLTTFYPQYIIDSK													YFHVGIQ													ALNSVTLGAGVRYN													QAKAQQITQEVSKAVDAS											KAILNQLIPNIT													DNYLVSGT													GLSAAQIAAIK												IDSVSPFYN													EHQLQTTDVLGQT													LGRAFSVNDK													GFQLGINYK	
4->34				328->342																			121->139																437->449																						238->256																									167->179																			313->326																				60->66																420->433			197->214																										82->93	345->352																		219->229																	40->48	299->311																			156->165		266->274		
1.209	1.168	1.164	1.138	1.1341.119	1.114	1.112	1.105	1.1001.094	1.093	1.089	1.084	1.083	1.078	1.075	
WP_017139894
.1 
 
40	 KDEVTHVGSLSAALAGLHPMQYDPKAPTQVMAALGH
YKNK 
QSVAVGVGYYFN 
TPQYVVQNEVKKLSVENK            
NFKLLSLGIFIILMQNSLVAAD          
FKSGVSNSVAIGNGSVASTSNEVSIGSDTVKRRLTN
V                                              
KSKVEVQDE             
NVGFTLKLG             
KNLVAGLA            
NAGVAVGSE  
NKNLVAGLS             
VGSKNLVAGA             
SNVVGGA             
SAKSTDAVNGKQLYNAVKGVE             
KNIVAGVG             
KNLVAGL             
KGSSSTVIGYKNTV             
NKVLGLNNT             
NNVLGLDNE             
NLALGYKNI             
NYIVGTF             
ESTVVGN             
KNIVAGA             
IGNKASVYG             
NLILGA             
IAGVGNI             
IKNLVNG             
NKVAGAENLVNG             
SSALGIGNT             
RNLVNG             
1515->156
6 
 
1606->162
3                  	
5->26                     	
1446->148
2                   	
1626->163
4              	
1588->159
6                	
295->302                	
1572->158
0                	
238->246                 	
278->287               	
85->91                 	
1488->150
8                         	
771->778               	
267->273               	
1377->139
0                  	
212->220              	
226->234              	
975->983                  	
44->50   
1226->123
2              
799->805  
1.160 
 
1.136 
1.132 
1.112
1.106
1.098 
1.094
1.093 
1.087 
1.087 
1.086
1.083
1.080 
1.075
1.072
1.068
1.059
1.056 
1.049
1.049
1.049
1.042 
1.042
1.039
1.039
1.037
1.034 
1.033 
1.032 
1.031 
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DNVIAG             
NKIVGSF             
GKYSTA             
GSGVEYN             
TDNYVAGR             
KNLVAG             
KNLVKGS             
VAGIGNKV             
KNIIAG             
SNKVAGA             
SNKVAGA             
KGISNT            	
1083->109
1                   
254->259                
760->766                
854->860              
863->874                              
1367->137
5                
841->846             
155->160                 
72->78                
1238->124
3                
1598->160
4             
1001->100
8                  
309->314                
813->819                
956->963                   
785->790  
575->581                
351->357    
201->206  
1.029 
1.028
1.028
1.027
1.022
1.020
1.016 
1.015
1.015
0.987
WP_023038391
.1 
 
28	 DGGVRIVVDVVEKENVVDLL            
ILIAFLFVISLTSFSTMVNLPIKSIEVVNNQQVPAS
LIKNT            IIGFVVFAD             
KSIVISSVKFI             
WLWSVYPYISY             
IDLILLID             
ALSFEVVENQ             
FEDVVLQPT             
LHISIVEGIVRKIEVKKM             
VKNIVITG             
AYKVVGGI             
PTSGVYGKFQVEGG             
ILGLYQAQGYTLVNI             
FSEVKPDAQVA             
SQKLVATI             
TSELLDITQL             
EKGVAVNT             
QGGVAYG             
ELFHEIDTVGFKVN            
FKNVKYEARSVPG             
LKTKDYVIDR             
TEALLADFN             
NVTLELRTYHRG             
GFALDFYDP             
RRLLATG             
PIGPLRF             
IFNVKEYDATVD             
GWPVGH 
82->101  
4->44                 
621->629                
117->127                 
505->515                    
345->352                
182->191                
71->79                   
258->275               
193->200               
568->575              
524->537                    
233->247                
167->177                   
605->612                 
134->143                   
103->110                  
360->366               
435->448                        
328->340             
291->300                     
55->63                 
549->560                 
402->410                
159->165              
667->673                
309->320                
676->681 	
1.203 
1.183
1.161
1.158
1.156
1.153
1.148
1.145
1.138
1.133
1.132
1.120
1.109
1.101
1.100
1.099
1.091
1.089
1.084
1.065
1.063
1.062
1.061
1.057
1.056
1.053
1.049
1.041 
WP_060675827
.1 
 
7	 MVMLFLLVFSLPALAVQALT                              
EFKLVQREA             
EAVKAKLLEFG             
DKSIVKAQYFDLLKN                        
MTIVLDE             
ITIVGHT             
13->32  
170->178               
126->136                 
76->90                   
62->68                   
102->108                
1.205 
1.129
1.124
1.114
1.069
1.069
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DRIVGIE  140->146 	 1.063	
WP_060676683
.1 
 
12	 LALVLGSLLVVGSVASAKEVMPAPTP           
PEKVVEYVEKPVIVYRDR            
ASYSVYMLPTFQVAYKPTDFVKLYAAAG            
YYGALEAYLYQHTPL             
AEASVLFDFADYL             
SVDVQYR             
TLDVRVRNYHSL            
YTWHQYKVI             
SSKVKAISRLEYK             
EYTLPLGFS             
AVELSFD             
YAPYDG  
4->29    
31->48                       
317->344                                   
266->280 
165->177                  
59->65               
106->117               
299->307                   
142->154                   
231->239                   
285->291   
210->215  
1.219 
1.164
1.135
1.114 
1.108
1.099
1.097
1.097
1.095
1.086
1.078 
1.050 
 
Table 3. Predicted exposed antigen of OMV carried outer membrane and extracellular proteins 
The exposed antigen peptides for 16 predicted outer membrane and extracellular proteins carried 
by OMVs were forecasted by EMBOSS.  6 to 83 antigen sequences are predicted on each protein; 
specifically, autotransporter protein (WP_008701556.1) contained 83 anticipated antigen 
sequence, which is most among the 16 proteins.				 	
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Table 4  B-cell Epitopes 
Accession BCPred 
Epitope 
BCPred 
Score 
FBCPred 
Epitope 
FBCPred 
Score 
A0A140PNL
7 
TGGAAGGAAVGA 
RDNQERELKAKL 
VGCTGFEAGNGG 
ASNSTPDGRLQN 
IIGKDTKGTLIG 
 
1 
0.996 
0.978 
0.975 
0.953 
 
TTGGAAGGAAVG 
RDNQERELKAKL 
VNGYTDNTGKDA 
PGGVTFASDSAN 
SNPIASNSTPDG 
VGCTGFEAGNGG 
NQELSQRRANAV 
 
1 
1 
0.995 
0.983 
0.971 
0.971 
0.941 
 
1 
 
A0A140PP9
8 
TEANKKPLEDII 
CSSTKTNRKTNV 
IEGYGEQNPADT 
 
0.997 
0.961 
0.951 
 
EDTEANKKPLED 
GEQNPADTNQTA 
TKTNRKTNVGVD 
FNEEGVTIRREG 
 
0.999 
0.999 
0.995 
0.97 
 
A0A140PUD
9 
KEVMPAPTPAPE 
RGTKGDGASDEY 
ENKTKSEDTDKD 
SKGNKKGQYYGA 
TNNSEAKNWRWQ 
VTFDGYNGGTNN 
SRLEYKQKSNDG 
DREVAPAWRPNG 
FEGGYDPYTWHQ 
NQTLDVRVRNYQ 
VYNGYDRYQGSF 
KFGLRPGYAHNW 
 
1 
0.996 
0.991 
0.979 
0.971 
0.971 
0.97 
0.967 
0.948 
0.946 
0.941 
0.914 
 
KEVMPAPTPAPE 
KSEDTDKDWANS 
VVEYVEKPVIVY 
NWSGHSNGGEGR 
TFDGYNGGTNNK 
PAWRPNGSVDVQ 
RGTKGDGASDEY 
NGSGYERASYEL 
RNFAVTNNSEAK 
SNDGAKHAEASV 
LSFDFEGGYDPY 
TTANVNFTKNQT 
LNFESEYTLPLG 
NVYNGYDRYQGS 
 
1 
1 
0.999 
0.999 
0.999 
0.998 
0.995 
0.993 
0.99 
0.989 
0.986 
0.97 
0.946 
0.926 
 
WP_008691
343.1 
 
EIGGEPQIPGET 
TASPKNTNTKIN 
NPELKSALQEYV 
FLKYAYDTRNSS 
EKAKKEAPETAN 
PNSEWAKKSEVL 
 
1 
0.992 
0.989 
0.961 
0.942 
0.929 
 
ETKIVEEVPVDE 
KLTASPKNTNTK 
EKAKKEAPETAN 
DSANESKDLENA 
KKVEDSVENDYT 
SETYKTNNPELK 
KAEPSGESYYDK 
1 
1 
1 
0.999 
0.999 
0.999 
0.999 
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KYAYDTRNSSLM 
NLGGKRDSGPIR 
EFPNSEWAKKSE 
AKYDFSEKEVYD 
EKMQDKKPEIYY 
 
0.998 
0.992 
0.988 
0.978 
0.952 
	
WP_008700
150.1 
FKKLKEKKKIEI 
NTSSNTNTEQMS 
NSNNSEISSRIN 
FTKTTTTIEEVG 
GSSEIQRKVAEK 
NNINNDVTVRNT 
IFEYYKKLKNSE 
PPNSNYRDSDNR 
  1 
0.999 
0.996 
0.994 
0.969 
0.919 
0.915 
0.911 
 
EVEEKQESNQYL 
NFKKLKEKKKIE 
NTSSNTNTEQMS 
EYRNAGSSKAKY 
TVFNFTKTTTTI 
SLNSNNSEISSR 
RDSDNRTLGSSE 
NDVTVRNTVKNV 
ASDNSEYSREFQ 
VAESRPDLDKSK 
NYYFREAQKYVS 
QEVNSNINSMVS 
DIFNLALKTNKE 
CSNLYKANKAYE 
 
1 
1 
1 
0.999 
0.998 
0.998 
0.995 
0.987 
0.984 
0.965 
0.944 
0.931 
0.917 
0.906 
 
 
WP_008700
266.1 
 
LGVGAGGGGGLV 
GNDNTINGNNNF 
GTPDGGRRIVNV 
GAFGDPNVVTGN 
NQGKENQELKEE 
TATGTGSTGLGI 
GGGNSYMIGNGN 
GAFGIGTYDEVN 
GNNVTIGSGIQN 
KNEVSTVDSSAF 
WKAKLGVGSGGV 
PTIEAGTGTSST 
SNDATTGKQLYQ 
KIDDVKDEVNHV 
TAIGYKNNVSGN 
AGVAIGGERRVK 
 
1 
1 
1 
0.999 
0.999 
0.998 
0.996 
0.989 
0.98 
0.976 
0.972 
0.957 
0.936 
0.921 
0.912 
0.91 
 
GVGAGGGGGLVN 
GSSVSESEVVSV 
NQGKENQELKEE 
LGNNSTVSSSNE 
NATSNDATTGKQ 
GTGSTGLGIDNT 
INNDASGEDSSA 
FGNDNTINGNNN 
GNTANEENSSAF 
KIDDVKDEVNHV 
KSGAFGDPNVVT 
GNTASGEDSSAF 
VLGNNVTIGSGI 
GNQNVTSGEGSS 
GHKNEVSTVDSS 
NTKNKEQDEKIK 
GVEYNETPQYVV 
NGGGNSYMIGNG 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
0.999 
0.999 
0.999 
0.999 
0.998 
0.997 
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GAFGIGTYDEVN 
DGDVSATSTDAV 
SGQSSSSFGHSN 
GRDSNGRKIESS 
GGRRIVNVREAR 
GERAYSSAVGYE 
QYDPKAPTQVMA 
GFNNEATSLEST 
PTIEAGTGTSST 
DLTAYSKRDASN 
 
0.994 
0.991 
0.991 
0.989 
0.989 
0.971 
0.97 
0.963 
0.942 
0.927 
 
WP_008700
372.1 
 
AGTGTNSTVAGV 
GAFGVGKATWNK 
NNKQAKENQELK 
KIDNVKDEVNHV 
LSNTATGMNSSA 
 
0.998 
0.998 
0.993 
0.948 
0.924 
 
KQAKENQELKAK 
GNGSTVSSSNEV 
LGNNVSIGSGIN 
GVNNEATKSYSS 
ADGEVSATSTDA 
RNSSAFGYNNAV 
GTVNTVSGKNSS 
SSAFGYNNAVTG 
SNTATGMNSSAV 
DNVKDEVNHVGS 
SGTDSSAFGDQN 
QYDPKAPTQVMA 
GSGVTYNEVPQY 
KAMQNSSSTGIE 
 
0.999 
0.997 
0.995 
0.993 
0.987 
0.986 
0.984 
0.979 
0.976 
0.975 
0.975 
0.97 
0.933 
0.908 
 
WP_008701
093.1 
 
GAGIGGVLGAQR 
QGNSGSMTSTST 
VNNPAEAKYWLQ 
KTGRNVQTSTRN 
 
1 
0.993 
0.962 
0.927 
 
QGNSGSMTSTST 
NLDSDNGFSDAA 
RIVNNPAEAKYW 
FNSAIPLLEDEL 
GAGIGGVLGAQR 
VQIRNTSGKNLN 
GRNVQTSTRNSV 
IWLEPAAANERT 
 
1 
0.999 
0.995 
0.988 
0.986 
0.983 
0.975 
0.913 
 
WP_008701
556.1 
 
RGEFEGDGGYKG 
GGYYDTNTNTLV 
GAPYKGRGDKPN 
1 
0.999 
0.997 
DTNTNTLVNTGN 
KSKAENEEQLKG 
TKVDTNAAVPNP 
1 
1 
1 
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LGKGIGWYAGIA 
EYYGDDPDDSTK 
LTGDKSTGIYGK 
AEEPIIEVEVSA 
TGSNSNTVGGAY 
GIEAAEYTNAKV 
TNAAVPNPDYLS 
GYQITTTNTSKI 
ITVGGTNYSNNR 
GHNVRGGVGLRV 
ETGQIIGGGHLP 
YVGASQPREHYS 
ENGNTKEADKVS 
AMYLLEDNEATT 
KIDTKKTPTEVE 
GSITGGKNIVGL 
EKDGTAFYYKLP 
NSDNVTGITIQN 
LNDNTGKISVGK 
NRKNNGKIGSIG 
NSVQTREEITTS 
LDSNTDSYNKMQ 
KSGIINFKDNNV 
GIYYSDKDKNGN 
FDEMKGKQYANV 
KFKFKDIGNSKE 
GERGIGMYATGY 
 
0.996 
0.994 
0.994 
0.991 
0.987 
0.987 
0.986 
0.985 
0.98 
0.979 
0.978 
0.969 
0.968 
0.965 
0.963 
0.957 
0.953 
0.946 
0.946 
0.943 
0.942 
0.938 
0.936 
0.931 
0.927 
0.909 
0.903 
 
EEPIIEVEVSAG 
NSDNVTGITIQN 
RGEFEGDGGYKG 
NSVQTREEITTS 
EYYGDDPDDSTK 
NSDNMAATNNKK 
KNSGSITGGKNI 
LYGYQITTTNTS 
LLEDNEATTMGG 
GAPYKGRGDKPN 
NAKNNSLVRLER 
LTGDKSTGIYGK 
KFKDIGNSKEEQ 
TKGDGVANGYDV 
KPYDDNNSLNWT 
LLNDNTGKISVG 
TGSNSNTVGGAY 
NRKNNGKIGSIG 
NHTTLRSNGDQN 
YVGASQPREHYS 
NGNTKEADKVSL 
GGGHLPTTEEDY 
NQRIGVNANVGY 
YKYYFGTKSLTT 
YTNPIQNLNLLS 
GGTNYSNNRSAI 
IPPLPDFEAPNE 
EITGSQNYIPYS 
YGMNAKYGGKII 
DVNLDSNTDSYN 
SAAINFSYPWKG 
GKGIGWYAGIAH 
SAPNKITTLTIG 
TVPQANDKSIAP 
GSIGIYYSDKDK 
1 
1 
1 
1 
1 
1 
1 
0.999 
0.998 
0.998 
0.998 
0.997 
0.997 
0.997 
0.997 
0.997 
0.996 
0.994 
0.993 
0.993 
0.992 
0.992 
0.991 
0.991 
0.989 
0.989 
0.987 
0.987 
0.987 
0.986 
0.983 
0.982 
0.982 
0.981 
0.98 
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INAVANKSGIIN 
TAFYYKLPNNGN 
TFSGDATYTPVL 
THGVNFTSSIVN 
VDYKNTAYGVVY 
DSITEDNATSGG 
WYNLRGEKEDRR 
NTPKNLYTEGTI 
NIQGDLKAEIEK 
NGGDSSHFGTTD 
GNIEVHGERGIG 
NEIFNAKSKYYT 
VTYIRVKDKKSV 
PYTNFAKKSDSY 
LKKEWRTASKDS 
NVNISNGKIDIT 
QQYGFFSNNNGG 
GIEAAEYTNAKV 
 
0.979 
0.976 
0.972 
0.969 
0.969 
0.968 
0.967 
0.959 
0.958 
0.95 
0.95 
0.948 
0.947 
0.938 
0.937 
0.93 
0.929 
0.915 
 
WP_008702
403.1 
 
KNNTKEAKKLYD 
AKENNEAAKKAY 
AELPIEEERTYY 
YKKGKYEEALKK 
GDPERAEQIYKT 
NNSSANTNDASV 
TKENYEKALDYY 
AVKNNKELKAYS 
LSLAQDESSVNY 
EKQSQKEEYASY 
TPASEYSRKAAL 
SNRKDEAKVRFY 
NEKNYEKAASLY 
 
1 
1 
0.999 
0.998 
0.997 
0.953 
0.946 
0.945 
0.944 
0.936 
0.925 
0.912 
0.9 
 
NNSSANTNDASV 
EQKKYDEMEQYL 
YFDKKDLSKAKK 
AKKDPKAVKEYE 
ELPIEEERTYYS 
YPNSNLRGTITN 
GDPERAEQIYKT 
EEKQSQKEEYAS 
AKKAYTEIINNK 
YDKQENVAEAEK 
LVKNNTKEAKKL 
NMTPASEYSRKA 
KKGKYEEALKKF 
LLNNSNSAMFYL 
LAQDESSVNYLK 
KNNKELKAYSME 
YFLEKNYKKAEE 
1 
1 
1 
1 
1 
1 
0.999 
0.999 
0.999 
0.997 
0.997 
0.996 
0.993 
0.987 
0.987 
0.984 
0.982 
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VYYNLKDYDKAI 
EFSKAMPNENKE 
RNFKTALTESEK 
YVTKENYEKALD 
TVNKNPDEYILY 
IESGDTDKAIES 
AKVRFYLEKLKG 
LGKYDEAEADFQ 
LLQYDKYKAYAS 
IMTLSLTGNTDA 
 
0.977 
0.967 
0.96 
0.957 
0.952 
0.947 
0.942 
0.934 
0.918 
0.908 
 
WP_016361
171.1 
 
CGGGGGGGGGGS 
PKPSTPSTPSNP 
NQERALKGPGAF 
EDKDGKTVDENG 
QTLFTTTDKTDL 
YAPNNYAETPGI 
EHGEEVLEVVRD 
TSTGDTVTGKIN 
PTQEVYEAAMAK 
KFSPTTTLGVAL 
TGNNSFSGGSKV 
WSAGNKGDKNAS 
DLPYGFYTAGRL 
LGENAEASSKNV 
DESPNPPYTKEA 
TNITRNPDGTIR 
KGTTAIIGGDYV 
GIAIPKDTTEID 
SEYKPYKGEGNL 
 
1 
1 
1 
0.999 
0.998 
0.996 
0.989 
0.987 
0.986 
0.982 
0.974 
0.969 
0.957 
0.952 
0.952 
0.952 
0.947 
0.942 
0.928 
 
SCGGGGGGGGGG 
PKPSTPSTPSNP 
EHGEEVLEVVRD 
NQERALKGPGAF 
LGENAEASSKNV 
RRGSFDESEASW 
TSTGDTVTGKIN 
TKFSPTTTLGVA 
DSEYKPYKGEGN 
DESPNPPYTKEA 
AGNKGDKNASVE 
TTTDKTDLSQDP 
TPGIDNKPNNKI 
FDNDIYGDGGLE 
NTDKRDLSYEGR 
GANSVEDKDGKT 
GAQEEGLRIRSG 
ENVEKVFEDLDQ 
RITNITRNPDGT 
DLPYGFYTAGRL 
DKLSSAGFEARY 
HLTGNNSFSGGS 
GGDYVAYAGSNT 
NISYYGDTTIFK 
VGYDVDNFDLIN 
1 
1 
1 
1 
1 
1 
1 
0.999 
0.999 
0.999 
0.998 
0.998 
0.997 
0.997 
0.995 
0.994 
0.994 
0.994 
0.993 
0.992 
0.992 
0.99 
0.986 
0.985 
0.977 
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EDKKWADSVFSA 
RYAGESKSDMVG 
STMGFTSATEMM 
IPKDTTEIDGSG 
FPTVTNPLDSQK 
ASPITVGTSGTL 
GSSYAAPKVTRA 
DGYASADTRVTG 
DENGHPLVPRRS 
PYFDNKLEKGWI 
 
0.975 
0.971 
0.97 
0.967 
0.96 
0.959 
0.946 
0.943 
0.913 
0.904 
 
WP_016361
319.1 
 
FFDFGGLAGGGK 
NPAGTARFEKGK 
AIKKQKTNEALT 
SPDYLSNQAQTG 
AQFKPLGIYDKG 
VTLGAGVRYNFD 
PSTEYKQAKAQQ 
FKEKYKVDENQK 
 
1 
0.992 
0.974 
0.966 
0.943 
0.94 
0.939 
0.928 
 
EKEEGNFKEKYK 
GGLAGGGKLNYD 
GIYDKGSSLTGE 
DSVSPFYNPAGT 
GRAFSVNDKLSF 
VNPSTEYKQAKA 
TYSPDYLSNQAQ 
TSTDDNGAYFFD 
GAGVRYNFDETL 
EHGRDYKDGWEV 
SFNDTEYALNSV 
 
1 
1 
0.999 
0.995 
0.98 
0.973 
0.964 
0.964 
0.964 
0.949 
0.906 
 
WP_017139
894.1 
 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
AGAGNGTVGNNN 
TTIGNNNTIGGS 
AGAGNGTVGDNN 
AGAGNGTVGDNN 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
KGENNTTSGKSN 
GGASQTTTGNNN 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
GAGNGTVGNNNK 
HDNITSGDNSLA 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
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AGAGNGTVGSNN 
AGAGNGTVGSNN 
AGAGNGTVGSNN 
AGAGNGTVGSNN 
LKGENNTTSGKS 
VAGAGNGTVGNK 
VAGAGNGTVGNK 
VAGAGNGTVGNK 
VVGGASQTTTGN 
GNNNKVIGNNNF 
TTTGNNNKIGGA 
GANNGTVGNNNK 
LNNTVKGNHNNV 
YGNDNTVNGNGS 
LSNKTTGNNNLI 
KTTGNGNNVLGT 
GNDNEVTGENSS 
GNDNEVTGENSS 
FNKTDGKNNYIV 
GNNSGAFGDPNT 
NKTTGDKNNITG 
TGASNTTKGDEN 
AGTDNGTVGDNN 
VAGAGNRTEGSK 
FGHDNITSGDNS 
FGHDNITSGDNS 
KNKTTGDKNLVA 
AGAGNKTAGNSN 
AGAGNKTAGNSN 
GANNGTVGDNNW 
AGANNGTVGSNN 
AGANNGTVGSNN 
AGANNGTVGSNN 
AGANNGTVGSNN 
AGANNGTVGDNN 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
0.999 
0.999 
0.999 
0.998 
0.998 
0.998 
0.998 
0.997 
0.996 
0.994 
0.994 
0.994 
0.993 
0.991 
0.991 
0.989 
0.985 
0.985 
0.983 
0.982 
0.982 
0.982 
0.982 
0.98 
HDNITSGDNSLA 
AGAGNGTVGDNN 
AGAGNGTVGDNN 
TTIGNNNTIGGS 
GANNGTVGNNNK 
GATNKTTGDKNN 
NKTTGNNNLILG 
TTTGNNNKIGGA 
NGIGNKTTGIKN 
AGAGNGTVGNKN 
AGAGNGTVGNKN 
AGAGNGTVGNKN 
AGAGNGTVGSNN 
AGAGNGTVGSNN 
AGAGNGTVGSNN 
AGAGNGTVGSNN 
YGNDNTVNGNGS 
GSFNKTTGNSNV 
TGASNTTKGDEN 
SGRSNETTGNNN 
GANNGTVGDNNW 
GANNGTVGDNNK 
AGTDNGTVGDNN 
EKIKNLEEKLEK 
NKTTGNGNNVLG 
NTNVGNSDITNG 
GDNNKVSGKDNL 
ENKELKSKVEVQ 
GVEYNETPQYVV 
GNNSGAFGDPNT 
DNEVTGENSSAF 
DNEVTGENSSAF 
ASNGTVGDNNKV 
LNNTVKGNHNNV 
GNGSVASTSNEV 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
0.999 
0.999 
0.999 
0.999 
0.999 
0.999 
0.999 
0.998 
0.998 
0.998 
0.998 
0.998 
0.998 
0.998 
0.998 
0.998 
0.997 
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SNETTGNNNIVS 
AGASNGTVGDNN 
RGNNNITDGRSN 
AGAGNRTEGYKN 
GLANKTTGDKNL 
AGASNGTVGSNN 
SNKTEGTSNEIL 
ENKELKSKVEVQ 
LGIGNTVKGSSS 
NGIGNKTTGIKN 
NTNVGNSDITNG 
 
0.979 
0.976 
0.975 
0.969 
0.956 
0.95 
0.949 
0.937 
0.928 
0.921 
0.902 
 
VEGEINNVKDEV 
NQNKVEGKESSA 
AGAGNKTEGNKN 
KNKTTGDKNLVA 
GANNGTVGSNNW 
GANNGTVGSNNW 
GANNGTVGSNNW 
GANNGTVGSNNW 
AGDDNKVAGIGN 
AGDDNKVAGIGN 
AGDDNKVAGIGN 
AGDDNKVAGIGN 
AGDDNKVAGIGN 
NGVANTTAGSRN 
GDGEYSAKSTDA 
AGAGNKTAGNSN 
AGAGNKTAGNSN 
IGDDNKVAGIGN 
AGAGNRTEGYKN 
LGRNNKVKGEDG 
GISNTLKGDSNK 
GRDNEAKGERNL 
GRDNEAKGERNL 
GKENETTGENSL 
SNKTEGTSNEIL 
ITFKSGVSNSVA 
QYDPKAPTQVMA 
IGNNNKVIGNNN 
GTFNKTEGNKNS 
GNNNITDGRSNE 
GASNGTVGSNNW 
VGEGNKTEGKYS 
VGEGNKTEGKYS 
LGRDNKVKGENS 
KGNIAKGNSSTA 
0.997 
0.995 
0.993 
0.992 
0.99 
0.99 
0.99 
0.99 
0.989 
0.989 
0.989 
0.989 
0.989 
0.988 
0.987 
0.984 
0.984 
0.981 
0.981 
0.978 
0.977 
0.975 
0.975 
0.973 
0.971 
0.971 
0.97 
0.968 
0.964 
0.958 
0.956 
0.953 
0.953 
0.952 
0.949 
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KGNIAKGNSSTA 
KENKTDGINSTA 
KENKTDGINSTA 
NGIGNKVAGAEN 
IADGRTNKITGD 
GLANKTTGDKNL 
VSGTENKVIGNK 
 
0.949 
0.946 
0.946 
0.943 
0.938 
0.908 
0.9 
 
WP_023038
391.1 
 
ARSVPGDPEGID 
NTPIGPLRFDFG 
GKFQVEGGHAGG 
LTTKPGSVQNYN 
ESQKFWVGGGNS 
FGHNIGTTAGVG 
TLREDTDKSIVI 
IVEGIVRKIEVK 
RGYDGGFFKGSQ 
LKDSNWRGKNQE 
VYPYISYDTRNN 
VGHKMDDDGMKF 
NRRTPNDDVLKT 
EKSNKDYTGFAL 
 
1 
0.999 
0.999 
0.999 
0.994 
0.988 
0.981 
0.973 
0.957 
0.956 
0.954 
0.943 
0.925 
0.919 
 
EARSVPGDPEGI 
VVDVVEKENVVD 
KFQVEGGHAGGY 
NTLREDTDKSIV 
QNYNNLREDRDK 
WLWSVYPYISYD 
GGGNSLRGYDGG 
VEGIVRKIEVKK 
FGHNIGTTAGVG 
NRRTPNDDVLKT 
VLQPTSYDGGVR 
VITGNHTIPTST 
EVVNNQQVPASL 
QGGVAYGSETGL 
RLNTPIGPLRFD 
NVKEYDATVDNL 
KTSYGDEDSELF 
TDMSTDENGTLH 
ADFNALKETGYF 
DSNWRGKNQEFG 
 
1 
1 
1 
1 
0.998 
0.998 
0.998 
0.997 
0.995 
0.99 
0.989 
0.989 
0.987 
0.981 
0.972 
0.969 
0.967 
0.957 
0.949 
0.902 
 
WP_060675
827.1 
 
KRKNSTTTTIMV 
TKEGRAQNRRVE 
GIEAMGEEQPIA 
DKSIVKAQYFDL 
 
0.996 
0.995 
0.909 
0.909 
 
KRKNSTTTTIMV 
FDFDKSIVKAQY 
YNFGLSRRRAEA 
DILNSEAPKEMT 
MGEEQPIATNAT 
LTTTQMRENSIR 
 
1 
1 
0.995 
0.964 
0.951 
0.913 
 
 
WP_060676
683.1 
KEVMPAPTPAPE 1 KEVMPAPTPAPE 1 
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 GGEGRDYAPYDG 
GTKGDASPDEYR 
SKGNKKGQYYGA 
DREVAPAWRPNG 
ISRLEYKQKDGS 
EDTDRDWARSRN 
FEGGYDPYTWHQ 
VYNGYDRYQGSF 
KNQTLDVRVRNY 
KFGLRPGYAHNW 
YQHTPLYKNNAV 
 
0.999 
0.999 
0.979 
0.967 
0.965 
0.962 
0.948 
0.941 
0.937 
0.914 
0.903 
 
WTGHSNGGEGRD 
ETENKTKSEDTD 
APYDGYDAGTNN 
RGTKGDASPDEY 
VVEYVEKPVIVY 
PAWRPNGSVDVQ 
LSFDFEGGYDPY 
TTANVNFTKNQT 
AKHAEASVLFDF 
SRLEYKQKDGSE 
YQHTPLYKNNAV 
LNFESEYTLPLG 
NVYNGYDRYQGS 
 
1 
1 
1 
0.999 
0.999 
0.998 
0.986 
0.97 
0.961 
0.953 
0.947 
0.946 
0.926 
 
 
Table 4. B-cell epitopes prediction  
B-cell epitope screening for the 16 outer membrane and extracellular proteins are predicted by 
BCPREDS. BCPred represents the result of fix length prediction method and FBCPred is for the 
flexible length prediction, only non-overlapping epitopes were reported. Protein WP_008701556.1 
and WP_008701556.1 contained much more epitope. 
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Table 5  T-cell Epitopes 
Accession HLA - A2 
epitope 
P value HLA – A3 
epitope 
P value HLA-
DRB1*0402 
P value 
WP_0163611
71.1 
 
 
MMIALASILFV 
SNKDSEVWFS
V 
VLMGATVQS
M 
NLPINPGTPSV 
AILDANFVNA
V 
TLTDVYTDV 
KFSPTTTLGV 
KMMMIALASI 
LLTSTGDTV 
KLQAYVTQA 
WMTADQIRQ
TL 
MMMIALASI 
KLMIPYFRDA 
SMSTMGFTSA
T 
FLVGARAEYV 
GLEHGEEVLEV 
KMLSAYVEL 
KIKIQNGTVSV 
ALKGPGAFM
NI 
SNTQVGFKNS
V 
MMSGEIYASA 
KLGLGTLHLT 
AILPTQEVYEA 
KTVDENGHPL
V 
KLMIPYFRDAV 
VLNPKAIVGY 
FGAFREITPV 
RLGLSHISSKV 
ILDANFVNAV 
GLSHISSKV 
GSVGWDYTYV 
GMLNQERAL 
VMADGTEGV 
GVYGNVDFRV 
 
0.00308 
0.00345 
0.00441 
0.00531 
0.00531 
0.00561 
0.00716 
0.00898 
0.00901 
0.00954 
0.0106 
0.0107 
0.0124 
0.0133 
0.0138 
0.0145 
0.0147 
0.0151 
0.0165 
0.0187 
0.0204 
0.0204 
0.0212 
0.0221 
0.0239 
0.0245 
0.0245 
0.0269 
0.0281 
0.0291 
0.0294 
0.0304 
0.0319 
0.0321 
0.0326 
0.0333 
0.0335 
0.0349 
0.0349 
 
SVFSAGL
QY 
KVKNYGT
VK 
VLSNGYV
TK 
KVFEDLD
QK 
GAFMNIS
YY 
ILGSVGW
DY 
EVYEAAM
AK 
QVGFKNS
VK 
GLRIRSG
QY 
TTLGVAL
NY 
GWFTPFI
GY 
KFYGVKQ
AK 
IIGGDYVA
Y 
GTIRSISSK 
MVGVSLY
GK 
SAYVELG
KK 
EITPVFGV
Y 
KSYDDSE
YK 
GIDNKPN
NK 
LINNVDA
QK 
ASVEAGL
PY 
LFIWSAG
NK 
TWIGFGA
FR 
VTRAAAL
VY 
 
0.000196 
0.0012 
0.00185 
0.00293 
0.00352 
0.00421 
0.00472 
0.00499 
0.00557 
0.00724 
0.00724 
0.00762 
0.00926 
0.0102 
0.0102 
0.0139 
0.0145 
0.0171 
0.0185 
0.0185 
0.0201 
0.0201 
0.0217 
0.0233 
0.0242 
0.0251 
0.0261 
0.028 
0.028 
0.0357 
0.0369 
0.0369 
0.0407 
0.0421 
0.0449 
0.0463 
0.0494 
 
 
GGYFVQFNI 
DRYYYWDG
N 
YKLNRRFFN 
TKSNVSFGI 
TNANAKNN
I 
KDYNKVES
C 
NWGNYSK
NK 
VVGFEMNS
S 
QHGRAAFV
N 
KDYFVITPN 
GVYLAGAN
W 
DDDNARLR
W 
NYGVRLNY
K 
TPSDNKNSI 
IPYNSLISG 
TRNVDKFS
V 
YDYDINTN
W 
VYGRQGIL
N 
IGIYAMNN
N 
KDSVVDFNI 
GIYYEGTGN 
QVNVTSGTI 
NMGYGQF
SN 
DKGVVTIN
N 
GNINVGNN
S 
NPNNTTM
AA 
GKYYGEYGI 
NVNFVKNA
V 
 
0.00161 
0.00161 
0.0031 
0.00424 
0.00575 
0.00619 
0.00718 
0.00718 
0.00829 
0.00956 
0.00956 
0.00956 
0.0103 
0.011 
0.011 
0.0118 
0.0118 
0.0126 
0.0126 
0.0135 
0.0135 
0.0145 
0.0154 
0.0165 
0.0176 
0.0176 
0.0176 
0.02 
0.0228 
0.0242 
0.0258 
0.0258 
0.0258 
0.0258 
0.0258 
0.0274 
0.0274 
0.0274 
0.0291 
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TKFSPTTTLGV 
AYAGSNTQV 
AMAKFGNQS
V 
GAFREITPV 
ALVYDKFSW
M 
KIQNGTVSV 
TLSRQNPSEYL 
KWADSVFSAG
L 
PINPGTPSV 
SFDESEASWGI 
VTGTERPTGL 
KLEKGWISV 
EMMSGEIYAS
A 
GNLPLPFAKV 
LLTSTGDTVT 
LMIPYFRDA 
SVGWDYTYV 
TVDENGHPL 
GMRTANVEV 
NLPLPFAKVHS 
DLSNRLSGL 
TKFSPTTTL 
SLYGKQDLPY 
KLSSAGFEA 
KKFGWFTPFI 
NLPLPFAKV 
YAAPKVTRA 
LVYDKFSWM 
KFGWFTPFI 
 
0.0349 
0.0351 
0.0351 
0.0365 
0.0378 
0.038 
0.0381 
0.0392 
0.0397 
0.0413 
0.0416 
0.0416 
0.0416 
0.0416 
0.0421 
0.0434 
0.0434 
0.0449 
0.0454 
0.0467 
0.0473 
0.0473 
0.0473 
0.0494 
 
QTLFTTT
DK 
MLNQER
ALK 
AEYVGNK
YK 
TYVENGQ
NK 
KVHSGDS
EK 
GRFTGSS
VK 
TSYFDNDI
Y 
LSRQNPS
EY 
RLSGLDN
FK 
DLEYAPN
NY 
SWGIKAD
KK 
ALKASLYT
A 
KLRRDGY
AS 
 
GILNVKGAL 
VRGKRAVGI 
NIKNTGTLN 
GDSKGIFS
M 
NNHRTKRY
S 
VYSNIQER
M 
GKDFTITSS 
GKNNVAAY
I 
KVSVTKKAI 
TEGNVAGN
L 
GVNQAKM
RN 
VDGNDLTS
T 
KDGYQYFN
R 
QKHYIKVEN 
TINMNRTTL 
GRGWIYSN
S 
GKYGWSAG
I 
NGANAKFE
N 
TDGNLKLSG 
PKAVTEKTI 
VGIYAKNTT 
GVYAVNGS
K 
GNKITLKNI 
DKSGTKDD
T 
QVGVAVKG
T 
LKGNVMA
GT 
TVKNGATGI 
VPLRTEIKT 
NYNYKIGGS 
NSNMNMT
LG 
DNANIAQS
G 
0.0291 
0.0291 
0.0291 
0.0309 
0.0309 
0.0309 
0.0328 
0.0328 
0.0328 
0.0348 
0.0348 
0.0348 
0.0348 
0.0348 
0.0348 
0.0369 
0.0369 
0.0369 
0.0369 
0.0369 
0.0369 
0.0391 
0.0391 
0.0391 
0.0414 
0.0414 
0.0438 
0.0438 
0.0438 
0.0438 
0.0438 
0.0438 
0.0463 
0.0463 
0.0463 
0.0489 
0.0489 
0.0489 
0.0489 
0.0489 
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GMAYREDA
S 
GKNTAATL
N 
TNTYTMKL
G 
GIYLAGTAS 
ISYGHIFNI 
DFARAVANI 
GIYTTNDNS 
SKNNIINTL 
GALNVADS
T 
YVDNTATS
K 
QDGGTITT
G 
QSNVTLNE
N 
TPPNEPNPS 
GVYVVDGE
A 
GIYGANGG
S 
GYNKTVNT
D 
NMDLTLNN
F 
SDDVIAFNL 
NIYLFAQGG 
LPSFSRGNS 
 
 
A0A140PU
D9 
 
 
YLFSNNFFKV 
KNWRWQPTA
WA 
SLLVVGSVASA 
ELYMLPTFQV 
LNFESEYTLPL 
YLFSNNFFK 
ALVLGSLLVV 
YLYQHTPLYK 
FLNFESEYTL 
LVLGSLLVV 
NVSRLQTTAN
V 
YTLPLGFSA 
 
0.000191 
0.00454 
0.0056 
0.006 
0.00686 
0.00804 
0.00898 
0.0124 
0.0131 
0.0163 
0.0239 
0.0253 
0.0257 
 
YLFSNNFF
K 
YLYQHTP
LY 
KVIANGS
GY 
TTANVNF
TK 
NVYNGYD
RY 
RWYGETE
NK 
TLDVRVR
NY 
AVTNNSE
AK 
 
0.000317 
0.000955 
0.00161 
0.00293 
0.00312 
0.00588 
0.00801 
0.0133 
0.0185 
0.0225 
0.0251 
0.0333 
0.0369 
 
APAWRPN
GS 
YRNFAVTN
N 
NWRWQPT
AW 
DVQYRWY
GE 
DWANSKN
NV 
WHQYKVIA
N 
DGYNGGTN
N 
ADYLFSNNF 
0.00458 
0.00619 
0.00718 
0.00772 
0.00829 
0.0118 
0.02 
0.0228 
0.0258 
0.0328 
0.0348 
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RWQPTAWAG
M 
KNWRWQPTA 
YLYQHTPLY 
LYMLPTFQV 
VLFDFADYLFS 
 
0.0278 
0.0304 
0.0319 
0.0326 
 
SYKPTDF
VK 
YVEKPVIV
Y 
TSRLEYKQ
K 
DFEGGYD
PY 
GLRPGYA
HN 
REYVTFD
GY 
GTNNKYF
LN 
VVGSVAS
AK 
 
0.0407 
0.0449 
0.0478 
 
GYDRYQGS
F 
NWSGHSN
GG 
IRHFYNFGN 
 
A0A140PS
K0  SILMLFAFV 
ALENNFWKVS
V 
MLFAFVACSS
T 
ALENNFWKV 
FVACSSTQFV 
KTMDSIPGASI 
IFLSILMLFA 
VLIQYFPTEF 
YLGTYQGII 
QYFPTEFEIAL 
VLIQYFPTE 
 
 
0.000765 
0.00345 
0.00478 
0.00674 
0.00803 
0.0212 
0.0234 
0.0365 
0.0398 
0.0467 
0.0494 
 
 
TCEGIGA
DY 
KALENNF
WK 
KRIAVYKF
K 
SATVTQA
VK 
 
 
0.00926 
0.0102 
0.0164 
0.0494 
0.000765 
 
 
NIIKTMDSI 
LKSNFAITC 
DYLGTYQGI 
 
 
0.00891 
           
0.0214 
           
0.0438 
 
A0A140PP
98  LLLALLVTA 
KLYAVLLLAL 
ILFDFDKYIV 
LLLALLVTACS 
NLILSMPELIL 
SLSTLAKAL 
NLILSMPEL 
ILFDFDKYI 
FIGTEAYNLEL 
 
 
0.00252 
0.00469 
0.00637 
0.00652 
0.0158 
0.0253 
0.0253 
0.0304 
0.0378 
 
 
FDFDKYIV
K 
SVKRANA
IK 
LVTACSST
K 
AVEDTEA
NK 
KLYAVLLL
A 
 
 
0.00801 
0.00971 
0.0133 
0.0164 
0.0185 
 
 
DKYIVKDKI 
GEQNPADT
N 
SRNRRVEFI 
TKTNRKTN
V 
MPELILFDF 
VTIRREGNN 
 
 
0.00829 
0.0135 
0.0135 
0.02 
0.02 
0.0258 
 
WP_00870
1980.1  TTLPSEPTIHI 
LLGDRSMGW
V 
FLSGSKVTV 
MLVDKPLSV 
VIMGWAYKHL 
 
0.000628 
0.00124 
0.00149 
0.00174 
0.00259 
 
FLINGGFS
Y 
ALYASGT
TK 
TLNNVIAY
Y 
 
3.37E-05 
0.000263 
0.000816 
0.00129 
0.00226 
 
GGYFVQFNI 
DRYYYWDG
N 
YKLNRRFFN 
TKSNVSFGI 
 
0.00161 
0.00161 
0.0031 
0.00424 
0.00575 
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KLGLHYQAPL 
TLTAPEEVAIV 
GLIDNQGTINV 
GLYGNKGTV 
NLLGNKVTL 
YLAGANWER 
GIYAKNTTV 
YLSGNSTAA 
GLFGTKKIGL 
TMVRIPYNSLI 
VMAGTNVNF
V 
KTLTSTGNITV 
LINNMNVTV 
SIINSNMNMT
L 
QLTDTNATGQ
V 
YLTKPIDLL 
YLNDREAFT 
ALGSIGKTLTV 
FLTLKNANSSI 
KLTLESPNGHI 
TMAAGSSVYL
T 
FLAQRLKATA 
GLVNIDATSKI 
ITVQSGSTITV 
TINMNRTTL 
FMADDTNPN
NT 
GLGSGSLNNL 
ITLESGSTLNV 
TLLGGGANPQ
A 
KLTQRGEFWV 
YDINTNWTV 
WLTRGEITV 
FLINGGFSYA 
MLVDKPLSVGI 
TVADKGVGLL
V 
RLSYSMALL 
LQHGRAAFV 
NLHGSSTAFD
V 
0.00277 
0.00308 
0.00326 
0.00357 
0.00382 
0.00382 
0.00435 
0.00435 
0.00469 
0.00478 
0.005 
0.00504 
0.00527 
0.0056 
0.0056 
0.00561 
0.00561 
0.00589 
0.0062 
0.00652 
0.00652 
0.00716 
0.00721 
0.00757 
0.00759 
0.00795 
0.00849 
0.00876 
0.00876 
0.00898 
0.00954 
0.0101 
0.0106 
0.0111 
0.0121 
0.0125 
0.0125 
0.0127 
0.0127 
0.0131 
0.0133 
0.0139 
0.0145 
GVYAVN
GSK 
GIYDKSGT
Y 
ASYGKN
MGY 
ALNGGGT
LK 
SLISGERY
K 
GLLVKGT
GK 
SVIMGW
AYK 
GVINAQK
HY 
GAIGAFIN
Y 
IVEKTVIK
K 
TLGVSGY
EY 
AVYSDGT
GK 
NILKGYQS
Y 
GVFTDGN
LK 
TAEGRG
WIY 
SISNNFDI
K 
GLKVDIIN
K 
GIETSIKSK 
GVTINYN
YK 
FVKNAVP
LY 
KTAVGIY
AK 
KLNSGTKI
K 
ASRSSILA
Y 
ILDSNNQ
EK 
GMYLDTA
VK 
YLAGTASL
K 
0.00242 
0.00258 
0.00331 
0.00331 
0.00397 
0.00421 
0.00472 
0.00472 
0.00557 
0.00588 
0.00653 
0.00653 
0.00688 
0.00762 
0.00762 
0.00801 
0.00801 
0.00801 
0.00801 
0.00841 
0.00841 
0.00926 
0.00926 
0.00971 
0.00971 
0.0107 
0.0107 
0.0112 
0.0112 
0.0112 
0.0112 
0.0112 
0.0117 
0.0117 
0.0117 
0.0122 
0.0128 
0.0128 
0.0133 
0.0133 
0.0139 
0.0145 
0.0151 
TNANAKNN
I 
KDYNKVES
C 
NWGNYSK
NK 
VVGFEMNS
S 
QHGRAAFV
N 
KDYFVITPN 
GVYLAGAN
W 
DDDNARLR
W 
NYGVRLNY
K 
TPSDNKNSI 
IPYNSLISG 
TRNVDKFS
V 
YDYDINTN
W 
VYGRQGIL
N 
IGIYAMNN
N 
KDSVVDFNI 
GIYYEGTGN 
QVNVTSGTI 
NMGYGQF
SN 
DKGVVTIN
N 
GNINVGNN
S 
NPNNTTM
AA 
GKYYGEYGI 
NVNFVKNA
V 
GILNVKGAL 
VRGKRAVGI 
NIKNTGTLN 
GDSKGIFS
M 
NNHRTKRY
S 
VYSNIQER
M 
0.00619 
0.00718 
0.00718 
0.00829 
0.00956 
0.00956 
0.00956 
0.0103 
0.011 
0.011 
0.0118 
0.0118 
0.0126 
0.0126 
0.0135 
0.0135 
0.0145 
0.0154 
0.0165 
0.0176 
0.0176 
0.0176 
0.02 
0.0228 
0.0242 
0.0258 
0.0258 
0.0258 
0.0258 
0.0258 
0.0274 
0.0274 
0.0274 
0.0291 
0.0291 
0.0291 
0.0291 
0.0309 
0.0309 
0.0309 
0.0328 
0.0328 
0.0328 
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TTLNNAGEINL 
LLGGGANPQA 
GILADRGTSSI 
TLNNFHVSA 
KLTFDLATGKL 
NNTDTTVTSH
L 
IALNGGGTLKV 
DLLGDRSMG
WV 
KLNRRFFNTL 
ALQGITVAAV 
GLIDNQGTI 
NLLALYANGL 
TLPSEPTIHI 
FIAQNTTFNV 
TLLNVPYSEFS 
NIQERMKTV 
FTITSSSTNKV 
HLVTNKGTV 
GLTVAGVSV 
TLKNIFNVSPS 
ITLKNIFNV 
TTTSDITMV 
KLTQRGEFWV
K 
SFANDNFNGQ
V 
LLVKGTGKTL 
SLGTNAKGLV 
IMADRTDAGA 
KFIAQNTTFNV 
VLPLGAVHQA 
LLFINKGNINL 
MTPPNEPNPS
V 
KLINNMNVTV 
GTMNINASSPI 
NVMAGTNVN
FV 
TIGSSGFTTPS 
FLKENSIGL 
GIYSQGGTV 
ILNITAPTA 
KLNSGTKIKV 
0.0145 
0.0145 
0.0145 
0.0145 
0.0145 
0.0147 
0.016 
0.016 
0.016 
0.0165 
0.0171 
0.0172 
0.018 
0.0189 
0.0195 
0.0199 
0.0209 
0.0212 
0.0212 
0.0214 
0.0214 
0.0214 
0.0221 
0.0224 
0.023 
0.023 
0.0234 
0.0239 
0.0239 
0.0239 
0.0241 
0.0241 
0.0241 
0.0245 
0.0245 
0.0253 
0.0253 
0.0253 
0.0253 
0.0253 
0.0253 
0.0253 
0.0265 
KMRNAST
GY 
FIFANWG
NY 
KTVENSF
DK 
SVGILGM
AY 
TQRGEF
WVK 
MLANAA
SGK 
SITGNVT
NY 
KLEYTGN
GY 
IAEKGYGL
Y 
GQFSNGK
YY 
IVGSNFEF
K 
QAKKDGY
QY 
IVASKDG
TK 
SVAKVSEL
K 
ITVNNHR
TK 
TFRAEYQ
GY 
KISGGTG
QK 
VIYTGGE
HK 
GLVNITN
EK 
GTSAAGI
YY 
ATELLFIN
K 
GAVHQA
FAK 
YVDNTAT
SK 
GANAKFE
NK 
GSNNSVG
LY 
SSTGLFGT
K 
0.0158 
0.0158 
0.0164 
0.0171 
0.0178 
0.0178 
0.0193 
0.0193 
0.0193 
0.0201 
0.0201 
0.0201 
0.0201 
0.0208 
0.0217 
0.0225 
0.0225 
0.0233 
0.0233 
0.0251 
0.0251 
0.0261 
0.0261 
0.0261 
0.027 
0.027 
0.028 
0.028 
0.029 
0.029 
0.029 
0.029 
0.03 
0.03 
0.03 
0.0311 
0.0311 
0.0311 
0.0322 
0.0322 
0.0322 
0.0333 
0.0333 
GKDFTITSS 
GKNNVAAY
I 
KVSVTKKAI 
TEGNVAGN
L 
GVNQAKM
RN 
VDGNDLTS
T 
KDGYQYFN
R 
QKHYIKVEN 
TINMNRTTL 
GRGWIYSN
S 
GKYGWSAG
I 
NGANAKFE
N 
TDGNLKLSG 
PKAVTEKTI 
VGIYAKNTT 
GVYAVNGS
K 
GNKITLKNI 
DKSGTKDD
T 
QVGVAVKG
T 
LKGNVMA
GT 
TVKNGATGI 
VPLRTEIKT 
NYNYKIGGS 
NSNMNMT
LG 
DNANIAQS
G 
GMAYREDA
S 
GKNTAATL
N 
TNTYTMKL
G 
GIYLAGTAS 
ISYGHIFNI 
DFARAVANI 
GIYTTNDNS 
0.0348 
0.0348 
0.0348 
0.0348 
0.0348 
0.0348 
0.0369 
0.0369 
0.0369 
0.0369 
0.0369 
0.0369 
0.0391 
0.0391 
0.0391 
0.0414 
0.0414 
0.0438 
0.0438 
0.0438 
0.0438 
0.0438 
0.0438 
0.0463 
0.0463 
0.0463 
0.0489 
0.0489 
0.0489 
0.0489 
0.0489 
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ALNGGGTLKV 
YITGNSTFR 
KLGKSSTGL 
TLNENSIGI 
ALYANGLKL 
ALNMEGLGL 
LLYGDGTNT 
ALQGITVAA 
SVTPPTVEV 
ITANATTTV 
EFLSGSKVTV 
KRLSYSMALLI 
KISAENIALV 
NYLDNEGTISA 
TMTIAEKGYG
L 
DMSDGNAKV
SV 
SVVDFNIAPTV 
LTQRGEFWV 
YATGEHSTI 
GLFAKDGGV 
KMYADGEGS
VI 
YFVITPNVGV 
RLRWLTRGEI 
RLITPPEVPA 
GLSVGMLANA 
GIYNETTGAV 
ITGSGSFLTL 
NMDLTLNNFH
V 
TVVDAKSISGV 
FVITPNVGV 
TMAAGSSVYL 
LNMEGLGLDV 
AMNNNTDTT
V 
KITANATTTV 
GMLANAASG
KT 
QITSATGKAHI 
GMYAKGGAL 
FLINGGFSYAD 
NLKRATGLTTV 
0.0265 
0.0269 
0.0269 
0.0269 
0.0269 
0.0269 
0.0269 
0.0269 
0.0278 
0.0278 
0.0278 
0.028 
0.0281 
0.0281 
0.0281 
0.0281 
0.0294 
0.0294 
0.0302 
0.0302 
0.0304 
0.0307 
0.0307 
0.0307 
0.0307 
0.0314 
0.0314 
0.0319 
0.0326 
0.0326 
0.0333 
0.0335 
0.0335 
0.0349 
0.0349 
0.0349 
0.0349 
0.0349 
0.0349 
0.0349 
0.0349 
0.0351 
0.0351 
TEFNYDV
TK 
PLEVKGK
DY 
GVSAGN
GGY 
AFVNAGE
IK 
NVSFGIA
AY 
IVGKITGT
K 
DVYSNIQ
ER 
TMAAGSS
VY 
YLAGAN
WER 
GILQDHS
SK 
GTAPTSG
TY 
DVIAFNLK
R 
ALYANGL
KL 
STHEKGN
IY 
SLDNISSH
R 
FSRGNSE
QK 
NIENATG
AK 
EAFTYGG
KY 
SLGLYAK
DK 
ATANGST
IK 
KSAEGIG
MY 
SGIGLYG
NK 
IIETTSGEK 
TVTVEGT
HK 
KVESCLKS
F 
KGKNNV
AAY 
0.0333 
0.0333 
0.0345 
0.0357 
0.0369 
0.0369 
0.0369 
0.0394 
0.0394 
0.0394 
0.0394 
0.0407 
0.0407 
0.0407 
0.0407 
0.0421 
0.0421 
0.0421 
0.0434 
0.0449 
0.0449 
0.0449 
0.0449 
0.0449 
0.0463 
0.0463 
0.0463 
0.0478 
0.0478 
0.0478 
0.0494 
0.0494 
 
SKNNIINTL 
GALNVADS
T 
YVDNTATS
K 
QDGGTITT
G 
QSNVTLNE
N 
TPPNEPNPS 
GVYVVDGE
A 
GIYGANGG
S 
GYNKTVNT
D 
NMDLTLNN
F 
SDDVIAFNL 
NIYLFAQGG 
LPSFSRGNS 
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KLNRRFFNT 
YLSGNSTAAY 
YLKGSGSNLL 
AIYGKNTAA 
DLTSTGTVTV 
YVFENITNA 
GLYVDNTAT 
FLAQRLKAT 
YLKGGEVDL 
FIVGKITGT 
YIFTTTHTG 
GTLNLTKTGA
V 
AVINLETEGNV 
TNVDETAINLV 
SLNNLFSGSTA 
TIKDVFRTGVV 
KLYHGVNQAK
M 
INANGEVIGM
V 
LTSTGTVTV 
YIPEHSKFI 
KLSGNGGLI 
GILNVKGALN
M 
ALASVAKVSEL 
ITAPSVTPPTV 
YLDNEGTISA 
GLYGAKGATI 
LTFDLATGKL 
IINSNMNMTL 
KLYHGVNQA 
ALGSIGKTL 
NVTPSTPEV 
VVTAGENLLAL 
LITPPEVPADI 
FVDKIDFGANI 
GMYLTKGSHL 
VINGGILNV 
GIYAKGVNV 
GIFSMGAGNV 
ATGEHSTITV 
FINKGNINL 
0.0351 
0.0351 
0.0364 
0.0364 
0.0364 
0.0365 
0.0365 
0.0365 
0.0378 
0.0378 
0.0378 
0.038 
0.038 
0.038 
0.038 
0.0381 
0.0381 
0.0381 
0.0392 
0.0392 
0.0392 
0.0397 
0.0398 
0.0398 
0.0413 
0.0413 
0.0416 
0.0416 
0.0416 
0.0421 
0.0431 
0.0434 
0.0434 
0.0449 
0.0449 
0.0449 
0.0449 
0.0451 
0.0451 
0.0454 
0.0454 
0.0454 
0.0467 
KLNRRFF
NT 
KLVGAYF
KD 
QNSNKFE
FY 
GHIFNIKE
K 
KKAIGIYA
K 
KVINGGIL
N 
GNNSVGI
YK 
SGLEDIRS
K 
STGNATI
GK 
KEAVGIY
AK 
NSIGLYG
AK 
LHYQAPL
NK 
ANNNGIG
VY 
TTVEVDG
VK 
STAAYAK
DK 
DFKSGIG
VY 
AGTGMY
LTK 
GNLSTAV
TK 
DASHNPI
VK 
HSKGSIG
VY 
AFSGDVK
SK 
ASAELGGI
K 
GKDSIGV
YK 
SYNELLSS
Y 
TGNSTFR
NK 
NVGSGIG
AY 
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SIIKTEVAV 
IAQSGNITV 
NVTPSTPEVA
A 
TAPSVTPPTV 
ITLTAPEEV 
ITLESGSTL 
TLESGSTLNV 
TLNLTKTGAV 
ALYASGTTKI 
KLGGDKGTGI 
TLKVSSAGQG
T 
AMTVGKDSIG
V 
SLGTNAKGL 
TINDKTASM 
LTSTGNITV 
ELNGENSVGA 
ALGSIGKTLT 
LLYGDGTNTY 
YIFTTTHTGG 
HLSGGKLEL 
GIYAEDSQV 
AVTNNGALNV
A 
TINAPTVTPPA 
YYWDGNDGA
I 
ILADRGTSSI 
LTAPEEVAIV 
DMSDGNAKV 
 
0.0467 
0.0467 
0.0467 
0.0473 
0.0473 
0.0484 
0.0484 
0.0486 
0.0486 
0.0486 
0.0494 
 
QSGSTITV
K 
TLTVADS
GY 
ITAPTAKD
K 
SIINSNM
NM 
LSWKNIIS
Y 
GNLDKSG
TK 
EKENNVV
NK 
KTALGSIG
K 
TITSSSTN
K 
GKGIGLF
AK 
ESNFNGP
EY 
VYTKSGY
NK 
KGKESVII
K 
NLISEKGI
Y 
KSTAKPD
TK 
TLTQSKD
SK 
 
 
Table 5. The T-cell epitopes prediction of the top five abundant proteins 
T-cell epitopes are predicted against HLA-A2, HLA-A3 and HLA-DRB1*0401 alleles 
individually. The p-value cut off was assigned as 0.05 for a balanced binding probability and 
specificity. The length of peptide against HLA-A2 ranged from 9 to 11, while for HLA-A3 the 
length was consistent with 9 residues.  Among the five selected proteins autotransporter proteins 
(WP_008701980.1) had most predicted T-cell epitopes follow by the most abundant 
autotransporter protein (WP_016361171.1) with 188 and 63 HLA-A2 peptides respectively. 
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Metabolic pathways and putative function  
The metabolic pathways of proteins from F. nucleatum OMVs were classified by KEGG based on 
previously identified protein functions, and 45 of 98 proteins were annotated. Thirty four percent 
were classified as proteins that participated in genetic information processing, while 18% were 
involved in environmental information processing, and 9% in cellular processes (Figure 14). 
Eighty five of the 98 proteins were functionally annotated by EggNOG 4.5.1 database, and 11 
groups were assigned (Figure 15.  In spite of their unknown functions, 20 proteins were mapped 
to translation, ribosomal structure and biogenesis, and 12 were placed in cell membrane biogenesis 
(Figure 15). Most of the autotransporter proteins were classified as unknown, though the most 
abundant one, WP_016361171.1, was identified as being involved in post-translational 
modification, protein turnover, and chaperones.  
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Figure 14  Metabolic pathway  
45 proteins are annotated in KEGG database. 34% of them are found evolving in genetic 
information process. 18% participate environmental information process, 9% contribute to cellular 
process, and 8% play role in carbohydrate metabolism. Subsequently, small portion mediate the 
amino acid metabolism (6%), energy metabolism (5%), lipid metabolism (4%), human disease 
(3%), metabolism of other amino acid (3%), and xenobiotic biodegradation (3%).   
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Figure 15  Function prediction of 85 protein annotated by EggNOG 4.5.1 database 
The protein function of F. ncleatum is not well characterized. The function for 27 out of the 85 
annotated proteins is unknown. In spite of unknown function, 20 proteins are packaged to 
translation, ribosomal structure and biogenesis, and 12 are mapped to cell 
wall/membrane/envelope biogenesis. Multiple proteins also mediate inorganic ion transport and 
metabolism (6), post-translational modification, protein turn over (5), lipid transport and 
metabolism (4), amino acid transport and metabolism (3), energy production and conversion (3).   
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Discussion  
Protein components of F. nucleatum 7_1 OMVs 
The OMV proteome of F. nucleatum has identified 157 and 190 proteins from the duplication 
experiment mass spectrometry analysis. Ninety-eight proteins were commonly identified in both 
OMV batches; 60 were predicted as secreted proteins with signal peptides. Among these secreted 
proteins, 16 were anticipated to be located in the outer membrane fractions, including extracellular 
proteins, which were the class of proteins most commonly seen in the OMVs. Outer membrane 
proteins consist of over half of the OMV protein residue totals, with others from cytosol, inner 
membrane, and periplasm fractions (Figure 12). By localization prediction of the 98 OMV proteins, 
cytosol proteins consist of half of the total, followed by the outer membrane, which is consistent 
with the previous findings 38, 63.  However, other studies with different Gram-negative bacteria 
indicated outer membrane (and extracellular) proteins were the major component of OMVs 64-65. 
This discrepancy was not likely to be caused by contamination as the applied purification methods 
were virtually identical. Rather, varying results may be due to differences in biochemical profiles 
across bacterial species and culture conditions 65-66. Some of the proteins found in OMVs may be 
secreted through non-classical pathways that are signal peptide independent. In this study, five 
cytosol proteins were predicted as being processed via non-classical secretion pathway; these had 
no predicted signal peptides (Table 2) 53. The overall variety of OMV proteins notwithstanding, it 
appears that outer membrane proteins are the predominant class carried by the OMVs.  
 
Type V secretion system 
Type V secretion is also called autotransporter secretion, as there is no net energy consumption in 
this Sec-dependent secretion system 67. Of all the 98 proteins reproducibly identified within F. 
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nucleatum OMVs, six autotransporter proteins were recognized and affirmed as the major 
component due to their copiousness, making up 31%~51% of the total protein load.  
Autotransporter proteins consist of three major domains: (1) the signal sequence at N-terminus 
that exports the protein through inner membrane; (2) the surface presenting passenger domain; and 
(3) the C-terminus β-barrel domain containing an autotransporter that modulates passenger domain 
exposure to surface 68-69. Most recognized autotransporter proteins are known or predicted 
virulence factors; the diversity in passenger domains of autotransporter proteins shows multiple 
virulence-associated functions, including adhesion and cytotoxin 69. For example, Fap2, an 
autotransporter protein of F. nucleatum, participates in multiple pathogenesis pathways, including 
binding to colorectal cancer cells, inducing lymphocyte apoptosis, and interacting with T cell 
immunoreceptors with Ig and ITIM domains (TIGIT) to facilitate immune evasion 21, 70-72. 
Functional sequence of the Fap2 is located on the passenger domain. Interestingly, the passenger 
domains of the six enriched autotransporter proteins surveyed in this study are heterogeneous.  
This suggests versatile pathogenic functions. In contrast, the C-terminal translocator domains are 
highly conserved (Figure 16) 68, 72. Sequence analysis demonstrated that four out of the six proteins 
(WP_008701980, WP_016361366.1, WP_016361171 and WP_020788899) had a high similarity 
and contained conserved domains of AidA, an adhesion protein involved in diffuse adhesion at the 
passenger portion 73.  AidA was identified as a versatile virulence factor in Escherichia coli, 
mediating adhesion, autoaggregation, biofilm formation, and invasion 74. After travelling across 
the outer membrane, AidA domain stays tethered to the surface and self-cleaves via autocatalytic 
action 75-76. The enrichment of autotransporter protein suggests that F. nucleatum OMVs may play 
a vital role in tissue colonization and invasion. Genetically modified autotransporters have been 
developed as platforms to expose multiple polypeptides on the OMV surface as antigens and to 
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explore their potential utility as vaccines 77. OMVs loaded with known antigenic autotransporter 
antigenic domains and epitopes may prove to be powerful tools for inducing effective immune 
responses in the host.  
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Figure 16  Sequence similarity of six autotransporter proteins 
The sequences of autotransporter proteins function domain are compared by BLAST. It reveals 
the C-terminal translocator domains are highly conserved and the passenger domain of the six 
enriched autotransporter protein are heterogeneous  	
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Putative virulence factor carried by OMVs and potential application  
Adhesion capability is crucial for bacterial pathogenesis, in particular for colonization and 
dissemination.  Adhesins mediate this activity, and thus are major virulence factors. However, 
domains of adhesins that are exposed for immune recognition can be exploited if used as potential 
antigenic components of vaccines, particularly those known to be bound to or contained within 
OMVs.  For vaccine delivery, antigen adherence and uptake are the first steps in eliciting immune 
response 34. F. nucleatum FadA is one highly antigenic virulence factor (among others), and has 
garnered attention as an effective immunogen, which can be incorporated into OMVs as a vaccine 
against F. nucleatum.  Previous studies have shown that FadA plays crucial role in F. nucleatum 
adhesion and invasion via binding to cadherin domains exposed on the host cell surface 26, 78. Two 
FadA proteins (WP_005910368.1 and A0A140PS00) were found to be incorporated into OMVs 
isolated from F. nucleatum. The sequence of A0A140PS00 is highly conserved with a previous 
characterized FadA gene (FN0264), suggesting that OMVs may have similar immunogenic 
characteristics 29. Another protein, one containing a MORN2 domain was found on OMVs. 
Previous studies analyzed by comparing whole-genome sequences suggested that proteins 
containing MORN2 may be involved in adhesion process, although the exact function has not been 
elucidated 79. Two more cell surface proteins identified were predicted to have key bacterial 
virulence factors and contain a YadA (Yersinia adhesin)-like domain with possible immunogenic 
properties. This domain was characterized on Yersinia as a crucial virulence factor mainly 
involved in adhesion and combating host defense by resisting serum killing activity and 
phagocytosis 80. All these putative virulence factors carried by F. nucleatum and other bacterial 
OMVs strongly suggest that these contain highly immunogenic domains and could prove useful if 
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incorporated into an OMV vaccine construct, as whole proteins or as recombinant fragments 
thereof.  
 
Furthermore, B-cell and T-cell epitope predictions give researchers an opportunity to tailor OMV 
preparations that can incorporate antigenic domains from known virulence factors that elicit B and 
T cell responses.  Exposed B-cell epitopes identified on OMV cargo proteins enhance the ability 
to induce effective antibodies against F. nucleatum.  In accordance with a previous study on human 
leukocyte antigen (HLA),  HLA-A2 and HLA-A3 are detected with dysregulated expression 
patterns in colon carcinomas tissues 58. HLA-DR disorders have also been thought to indicate colon 
cancer development  according to Maccalli, C., et al., and HLA-DRB1*1301 and HLA-
DRB1*0402 were found to be associated with CRC; however, no epitopes against HLA-
DRB1*1301 were found for the selected five proteins in our study 59.  Both T-cell and B-cell 
epitopes are able to stimulate long-acting and antigen-specific immune responses therefore have 
significant potential for vaccine development 81.  
 
Overall, OMV size ranges make these ideal for vesicular transport to lymph nodes and are readily 
recognizable by B cells.  OMVs containing moieties that have antigenic domains and epitopes are 
highly effective at triggering B cell activation, thereby stimulating a strong protective humoral 
immune response. Naturally secreted OMVs of F. nucleatum carry large quantities of 
autotransporter proteins. Thus, utilizing these OMV vehicles, which are already loaded with highly 
antigenic pathogen derived proteins, may facilitate the process of developing and expressing a 
large array of recombinant constructs for better optimized vaccines. OMVs of pathogens like F. 
nucleatum may serve as factories for the production of highly effective and molecularly designed 
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‘ready-made’ vaccines. Alternatively, OMVs can be utilized as delivery platforms loaded with one 
or just a few recombinant constructs proven to be highly antigenic. Our future studies will focus 
on the identity and verification of putative virulence factors carried by F. nucleatum OMVs and 
investigate the potential of these for vaccine design against F. nucleatum and colon cancer 
prevention. In conclusion, non-replicating OMVs from F. nucleatum have great potential for 
harnessing pathogen virulence factor antigenicity to produce an effective vaccine to combat CRC.  
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CHAPTER THREE 
CONCLUSION 
 
During the past several years, investigations into gut microbe role in human diseases, particular in 
carcinogenesis, has gained much attention. Detailed reviews of metagenomic data sets comparing 
healthy and diseased individuals have implicated invasive gut microbial lines in the onset or 
progression of diseases. F. nucleatum has recently emerged as being associated with, if not the 
causative agent of, colorectal cancer (CRC); however, mechanisms of F. nucleatum virulence 
factors in promoting tumorigenesis have only begun to be revealed. OMVs secreted by F. 
nucleatum and other Gram-negative bacteria participate multiple pathways to facilitate bacterial 
survival in the host. OMVs are highly immunogenic and have recently been developed as novel 
platforms for safe and efficient delivery of vaccines. Overall, the OMV size ranges make them 
ideal for vesicular transport to lymph nodes and are readily recognized by B cells. OMVs 
containing moieties that have antigenic domains and epitopes are highly effective at triggering B 
cell activation, thereby stimulating a strong protective antibody response. Naturally secreted 
OMVs of F. nucleatum carry large quantities of autotransporter proteins; utilizing these vehicles, 
which are already loaded with highly antigenic pathogen derived proteins may allow researchers 
to mitigate, if not to avoid, the labor-intensive process of developing and expressing a large array 
of recombinant constructs.  In other words, cultures of pathogens like F. nucleatum may serve as 
factories for the production of highly effective and specific ‘ready-made’ vaccines. Alternatively, 
OMVs can be utilized as delivery platforms loaded with one or just a few recombinant constructs 
proven to be highly antigenic.  
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Our future studies will focus on the identification and verification of putative virulence factors 
carried by F. nucleatum OMVs and investigate the potential for these in vaccine designs against 
colon cancer. The protective ability of F. nucleatum OMVs will be tested by inoculating into mice 
and evaluating the immune responses. Selected proteins with antigenic potential will be cloned 
and expressed as recombinant proteins (with C-terminal His6-tag for protein purification). 
Individual purified proteins will be injected into mice and monitored for immune responses. 
Further assays will be used to identify the protective activity of putative vaccine candidates. 
Additionally, specific protein mutant strains will also be constructed to explore target protein 
function.  
 
We have characterized the proteome of OMVs from F. nucleatum and provide topological analysis 
of proteins these contain; OMVs have been found to be enriched with autotransporter proteins. 
This suggests that OMVs may represent important cargo carrying functions and provide specific 
pathways for virulence and nutrient resources. In conclusion, non-replicating OMVs from F. 
nucleatum have great potential for harnessing pathogen virulence factor antigenicity to produce an 
effective vaccine to combat CRC.  The abundant autotransporter proteins carried by OMVs are 
expected to elicit sufficient immune responses. Moreover, numerous antigenic epitopes exposed 
on nanoparticles are designed to trigger robust B cells and T cell responses.  
 
